



Belgian Cancer Registry

# CANCER FACT SHEET 2022

## HEAD AND NECK CANCER

ICD-10 C00-C14; C30-C32



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

**HPV:** Human Papillomavirus is a sexually transmitted infection and a risk factor for the development of some H&N cancers.

### H&N cancer is divided in sub-locations according to ICD-10 codes:

- **Lip:** C00
- **Oral cavity:** C02-C05.0; C06
- **Oropharynx:** C01; C05.1-C05.9; C09-C10

- **Nasopharynx:** C11
- **Hypopharynx:** C12-C13
- **Larynx:** C32
- **Nasal cavity and paranasal sinuses:** C30-C31
- **Salivary glands:** C07-C08
- **Other and ill-defined sites:** C14



1. CANCER INCIDENCE .....	5
1.1. Head & Neck cancer incidence: by region .....	5
1.1.1. Head & Neck cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Head & Neck cancer incidence: by tumour stage .....	7
1.2.2. Head & Neck cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
1.2.3. Head & Neck cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.4. Head & Neck cancer incidence by stage (Stage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	8
1.2.5. Head & Neck cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	9
2. CANCER INCIDENCE TRENDS .....	12
2.1. Head & Neck cancer incidence trends: by region.....	12
2.1.1. Head & Neck cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	12
2.1.2. Head & Neck cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	13
2.2. Head & Neck cancer incidence trends: by tumour stage .....	14
2.2.3. Head & Neck cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards...	14
2.3. Head & Neck cancer incidence trends: by age group .....	16
2.3.4. Head & Neck cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	16
2.3.5. Head & Neck cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	17
3. CANCER PREVALENCE .....	18
3.1. Head & Neck cancer prevalence: by region.....	18
3.1.1. Head & Neck cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022 .....	18
4. CANCER SURVIVAL.....	19
4.1. Head & Neck cancer survival: by region .....	19
4.1.1. Head & Neck cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022.....	19
4.2. Head & Neck cancer survival: by sub-location and tumour stage.....	21
4.2.2. Head & Neck cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022.....	21
4.2.3. Head & Neck cancer survival by sub-location, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022.....	27
4.2.4. Head & Neck cancer survival by sub-location, stage (Stage) and sex: number at risk and net survival probabilities, 2013-2022 .....	33

5. CANCER SURVIVAL TRENDS.....	40
5.1. Head & Neck cancer survival trends: by tumour stage.....	40
5.1.1. Head & Neck cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022 .....	40
6. CANCER MORTALITY .....	42
6.1. Head & Neck cancer mortality: by region.....	42
6.1.1. Head & Neck cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021 .....	42
7. CANCER MORTALITY TRENDS.....	44
7.1. Head & Neck cancer mortality trends: by region .....	44
7.1.1. Head & Neck cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	44
7.1.2. Head & Neck cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	46

## 1. CANCER INCIDENCE



### 1.1. Head & Neck cancer incidence: by region

1.1.1. *Head & Neck cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
<b>Belgium</b>	0	0	1	3	4	6	9	19	28	47	127	252	384	379	266	193	124	69	27	5	1,943	35.1
	[0.0]	[0.0]	[0.3]	[0.9]	[1.2]	[1.6]	[2.4]	[5.1]	[7.4]	[12.5]	[32.1]	[62.4]	[104.1]	[121.3]	[100.8]	[101.5]	[97.9]	[88.0]	[89.9]	[85.5]	[34.0]	(33.5; 36.7)
Brussels	0	0	0	0	1	1	2	2	4	6	15	23	37	17	14	13	10	5	1	1	152	35.5
	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[2.0]	[3.9]	[4.3]	[8.7]	[13.8]	[37.1]	[66.3]	[132.3]	[80.3]	[84.7]	[106.8]	[123.8]	[98.3]	[46.1]	[187.6]	[25.3]	(29.7; 41.3)
Flanders	0	0	1	2	2	5	3	13	15	25	71	128	203	221	155	111	80	50	20	2	1,107	32.6
	[0.0]	[0.0]	[0.5]	[1.1]	[1.1]	[2.5]	[1.4]	[6.2]	[6.9]	[11.8]	[30.7]	[52.4]	[90.3]	[115.1]	[95.9]	[89.9]	[95.7]	[95.3]	[100.4]	[52.9]	[33.4]	(30.6; 34.5)
Wallonia	0	0	0	1	1	0	4	4	9	16	41	101	144	141	97	69	34	14	6	2	684	39.8
	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[0.0]	[3.4]	[3.5]	[7.8]	[13.3]	[32.9]	[80.7]	[124.0]	[142.1]	[113.0]	[126.4]	[97.2]	[67.0]	[75.7]	[130.0]	[38.2]	(36.8; 42.9)
Females																						
<b>Belgium</b>	0	0	1	1	4	3	7	9	22	26	48	93	119	143	104	94	55	27	14	8	778	12.7
	[0.0]	[0.0]	[0.3]	[0.3]	[1.2]	[0.8]	[1.8]	[2.4]	[5.8]	[7.1]	[12.4]	[23.3]	[31.6]	[43.0]	[35.2]	[40.7]	[30.9]	[20.0]	[20.2]	[39.0]	[13.2]	(11.8; 13.6)
Brussels	0	0	0	0	0	0	0	1	3	4	5	6	8	7	6	12	4	1	0	1	58	11.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[6.7]	[9.9]	[13.4]	[17.8]	[26.9]	[28.1]	[28.1]	[69.6]	[30.7]	[9.9]	[0.0]	[48.5]	[9.3]	(8.7; 14.8)

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
Flanders	0	0	0	1	4	1	3	5	11	11	25	43	64	81	65	49	37	20	10	5	435	11.8
	[0.0]	[0.0]	[0.0]	[0.6]	[2.2]	[0.5]	[1.4]	[2.4]	[5.1]	[5.3]	[11.1]	[18.1]	[28.5]	[41.0]	[37.4]	[34.3]	[33.0]	[23.5]	[23.5]	[41.4]	[12.9]	(10.7; 12.9)
Wallonia	0	0	1	0	0	2	4	3	8	11	18	44	47	55	33	33	14	6	4	2	285	14.6
	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.9]	[3.4]	[2.6]	[6.9]	[9.2]	[14.5]	[34.7]	[38.4]	[50.0]	[32.9]	[46.6]	[26.3]	[15.2]	[19.0]	[31.4]	[15.2]	(12.9; 16.3)

## 1.2. Head & Neck cancer incidence: by tumour stage

1.2.2. Head & Neck cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
<b>I</b>	108 [3.2]	226 [23.9]	90 [20.9]	424 [7.4]	7.7 (6.9; 8.4)	65 [2.0]	81 [8.1]	37 [5.8]	183 [3.1]	3.0 (2.6; 3.5)
<b>II</b>	78 [2.3]	144 [15.2]	77 [17.9]	299 [5.2]	5.5 (4.8; 6.1)	44 [1.3]	63 [6.3]	29 [4.6]	137 [2.3]	2.3 (1.9; 2.7)
<b>III</b>	74 [2.2]	155 [16.4]	77 [17.9]	307 [5.4]	5.6 (4.9; 6.2)	33 [1.0]	58 [5.8]	24 [3.8]	115 [2.0]	1.9 (1.5; 2.2)
<b>IV</b>	185 [5.5]	410 [43.4]	130 [30.2]	725 [12.7]	13.0 (12.0; 13.9)	55 [1.7]	124 [12.3]	78 [12.3]	257 [4.4]	4.1 (3.6; 4.6)
<b>X/NA</b>	50 [1.5]	94 [9.9]	44 [10.2]	188 [3.3]	3.4 (2.9; 3.9)	16 [0.5]	40 [4.0]	30 [4.7]	86 [1.5]	1.4 (1.1; 1.7)

1.2.3. Head & Neck cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	69 [2.1]	149 [15.8]	57 [13.2]	275 [4.8]	5.0 (4.4; 5.6)	56 [1.7]	71 [7.1]	25 [3.9]	152 [2.6]	2.5 (2.1; 2.9)
II	36 [1.1]	75 [7.9]	25 [5.8]	136 [2.4]	2.5 (2.0; 2.9)	19 [0.6]	27 [2.7]	18 [2.8]	65 [1.1]	1.1 (0.8; 1.3)
III	35 [1.0]	63 [6.7]	19 [4.4]	117 [2.0]	2.1 (1.7; 2.4)	15 [0.5]	16 [1.6]	15 [2.4]	46 [0.8]	0.8 (0.5; 1.0)
IV	61 [1.8]	140 [14.8]	41 [9.5]	243 [4.3]	4.4 (3.8; 4.9)	22 [0.7]	59 [5.9]	15 [2.4]	96 [1.6]	1.6 (1.3; 1.9)
X/NA	294 [8.8]	602 [63.7]	276 [64.0]	1,172 [20.5]	21.2 (20.0; 22.5)	101 [3.1]	193 [19.2]	125 [19.7]	419 [7.1]	6.8 (6.1; 7.4)

1.2.4. Head & Neck cancer incidence by stage (Stage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	114 [3.4]	245 [25.9]	91 [21.1]	450 [7.9]	8.1 (7.4; 8.9)	73 [2.2]	94 [9.4]	36 [5.7]	203 [3.5]	3.4 (2.9; 3.8)
II	78 [2.3]	155 [16.4]	78 [18.1]	311 [5.4]	5.7 (5.0; 6.3)	39 [1.2]	62 [6.2]	30 [4.7]	132 [2.2]	2.2 (1.8; 2.6)
III	81 [2.4]	160 [16.9]	79 [18.3]	320 [5.6]	5.8 (5.1; 6.4)	33 [1.0]	53 [5.3]	32 [5.0]	118 [2.0]	1.9 (1.6; 2.3)
IV	184 [5.5]	407 [43.0]	140 [32.5]	732 [12.8]	13.2 (12.2; 14.1)	58 [1.8]	138 [13.7]	79 [12.5]	275 [4.7]	4.4 (3.9; 4.9)
X/NA	38 [1.1]	62 [6.6]	30 [7.0]	130 [2.3]	2.4 (2.0; 2.8)	10 [0.3]	19 [1.9]	21 [3.3]	50 [0.9]	0.8 (0.6; 1.0)



1.2.5. Head & Neck cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Sub-locations	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages	15-59	60-74	75+	All ages		
Lip C00	I	2 [0.1]	4 [0.4]	5 [1.2]	11 [0.2]	0.2 (0.1; 0.4)	4 [0.1]	4 [0.4]	4 [0.6]	12 [0.2]	0.2 (0.1; 0.3)
	II	0 [0.0]	3 [0.3]	2 [0.5]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	2 [0.3]	2 [0.0]	0.0 (0.0; 0.1)
	III	0 [0.0]	1 [0.1]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	IV	1 [0.0]	1 [0.1]	1 [0.2]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
	X/NA	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Oral cavity C02-C05.0;C06	I	28 [0.8]	58 [6.1]	15 [3.5]	101 [1.8]	1.8 (1.4; 2.2)	19 [0.6]	28 [2.8]	11 [1.7]	58 [1.0]	1.0 (0.7; 1.2)
	II	21 [0.6]	42 [4.4]	13 [3.0]	76 [1.3]	1.4 (1.1; 1.7)	13 [0.4]	18 [1.8]	16 [2.5]	47 [0.8]	0.8 (0.5; 1.0)
	III	30 [0.9]	37 [3.9]	16 [3.7]	83 [1.5]	1.5 (1.2; 1.8)	10 [0.3]	14 [1.4]	14 [2.2]	38 [0.6]	0.6 (0.4; 0.8)
	IV	44 [1.3]	109 [11.5]	38 [8.8]	192 [3.4]	3.5 (3.0; 3.9)	14 [0.4]	48 [4.8]	44 [6.9]	106 [1.8]	1.6 (1.3; 2.0)
	X/NA	4 [0.1]	6 [0.6]	4 [0.9]	14 [0.2]	0.3 (0.1; 0.4)	4 [0.1]	2 [0.2]	5 [0.8]	11 [0.2]	0.2 (0.1; 0.3)
Pharynx C01;C05.1-C05.9;C09-C13	I	44 [1.3]	83 [8.8]	17 [3.9]	144 [2.5]	2.5 (2.1; 2.9)	23 [0.7]	29 [2.9]	14 [2.2]	66 [1.1]	1.1 (0.8; 1.4)
	II	36 [1.1]	66 [7.0]	32 [7.4]	134 [2.3]	2.4 (2.0; 2.8)	14 [0.4]	24 [2.4]	9 [1.4]	47 [0.8]	0.8 (0.6; 1.0)
	III	35 [1.0]	63 [6.7]	22 [5.1]	120 [2.1]	2.2 (1.8; 2.5)	14 [0.4]	25 [2.5]	7 [1.1]	46 [0.8]	0.8 (0.5; 1.0)
	IV	96 [2.9]	201 [21.3]	58 [13.5]	355 [6.2]	6.3 (5.7; 7.0)	33 [1.0]	64 [6.4]	22 [3.5]	119 [2.0]	2.0 (1.6; 2.3)
	X/NA	12 [0.4]	29 [3.1]	10 [2.3]	51 [0.9]	0.9 (0.7; 1.2)	3 [0.1]	10 [1.0]	4 [0.6]	17 [0.3]	0.3 (0.1; 0.4)
Oropharynx C01;C05.1-C05.9;C09-C10	I	42 [1.3]	78 [8.2]	16 [3.7]	136 [2.4]	2.4 (2.0; 2.8)	16 [0.5]	27 [2.7]	12 [1.9]	55 [0.9]	0.9 (0.7; 1.2)
	II	24 [0.7]	53 [5.6]	23 [5.3]	100 [1.8]	1.8 (1.5; 2.2)	7 [0.2]	21 [2.1]	6 [0.9]	34 [0.6]	0.6 (0.4; 0.8)
	III	23 [0.7]	40 [4.2]	18 [4.2]	81 [1.4]	1.5 (1.1; 1.8)	6 [0.2]	19 [1.9]	5 [0.8]	30 [0.5]	0.5 (0.3; 0.7)
	IV	50 [1.5]	102 [10.8]	31 [7.2]	183 [3.2]	3.2 (2.8; 3.7)	20 [0.6]	49 [4.9]	13 [2.1]	82 [1.4]	1.4 (1.1; 1.6)
	X/NA	10 [0.3]	21 [2.2]	9 [2.1]	40 [0.7]	0.7 (0.5; 1.0)	3 [0.1]	6 [0.6]	4 [0.6]	13 [0.2]	0.2 (0.1; 0.3)
Nasopharynx C11	I	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	4 [0.1]	1 [0.1]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)

Sub-locations	Stage	Males					Females					
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)			
		15-59	60-74	75+	All ages			15-59	60-74	75+	All ages	
	<b>II</b>	6 [0.2]	3 [0.3]	2 [0.5]	11 [0.2]	0.2 (0.1; 0.3)		6 [0.2]	1 [0.1]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)
	<b>III</b>	5 [0.1]	6 [0.6]	1 [0.2]	12 [0.2]	0.2 (0.1; 0.3)		5 [0.2]	1 [0.1]	0 [0.0]	6 [0.1]	0.1 (0.0; 0.2)
	<b>IV</b>	10 [0.3]	4 [0.4]	2 [0.5]	16 [0.3]	0.3 (0.1; 0.4)		5 [0.2]	2 [0.2]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)
	<b>X/NA</b>	1 [0.0]	1 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)		0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Hypopharynx C12-C13	<b>I</b>	1 [0.0]	5 [0.5]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)		3 [0.1]	1 [0.1]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
	<b>II</b>	6 [0.2]	10 [1.1]	7 [1.6]	23 [0.4]	0.4 (0.2; 0.6)		1 [0.0]	2 [0.2]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
	<b>III</b>	7 [0.2]	17 [1.8]	3 [0.7]	27 [0.5]	0.5 (0.3; 0.7)		3 [0.1]	5 [0.5]	2 [0.3]	10 [0.2]	0.2 (0.1; 0.3)
	<b>IV</b>	36 [1.1]	95 [10.0]	25 [5.8]	156 [2.7]	2.8 (2.3; 3.2)		8 [0.2]	13 [1.3]	8 [1.3]	29 [0.5]	0.5 (0.3; 0.6)
	<b>X/NA</b>	1 [0.0]	7 [0.7]	1 [0.2]	9 [0.2]	0.2 (0.1; 0.3)		0 [0.0]	4 [0.4]	0 [0.0]	4 [0.1]	0.1 (0.0; 0.1)
Larynx C32	<b>I</b>	26 [0.8]	92 [9.7]	50 [11.6]	168 [2.9]	3.1 (2.6; 3.6)		8 [0.2]	18 [1.8]	6 [0.9]	32 [0.5]	0.5 (0.3; 0.7)
	<b>II</b>	13 [0.4]	27 [2.9]	22 [5.1]	62 [1.1]	1.1 (0.9; 1.4)		3 [0.1]	13 [1.3]	1 [0.2]	17 [0.3]	0.3 (0.1; 0.4)
	<b>III</b>	11 [0.3]	44 [4.7]	27 [6.3]	82 [1.4]	1.5 (1.2; 1.8)		3 [0.1]	7 [0.7]	5 [0.8]	15 [0.3]	0.2 (0.1; 0.4)
	<b>IV</b>	25 [0.7]	77 [8.1]	23 [5.3]	125 [2.2]	2.3 (1.9; 2.7)		6 [0.2]	16 [1.6]	4 [0.6]	26 [0.4]	0.4 (0.3; 0.6)
	<b>X/NA</b>	6 [0.2]	7 [0.7]	6 [1.4]	19 [0.3]	0.4 (0.2; 0.5)		1 [0.0]	0 [0.0]	3 [0.5]	4 [0.1]	0.1 (0.0; 0.1)
Nasal cavity and paranasal sinuses C30-C31	<b>I</b>	5 [0.1]	7 [0.7]	2 [0.5]	14 [0.2]	0.3 (0.1; 0.4)		4 [0.1]	4 [0.4]	0 [0.0]	8 [0.1]	0.1 (0.0; 0.2)
	<b>II</b>	2 [0.1]	7 [0.7]	2 [0.5]	11 [0.2]	0.2 (0.1; 0.3)		4 [0.1]	1 [0.1]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)
	<b>III</b>	3 [0.1]	10 [1.1]	10 [2.3]	23 [0.4]	0.4 (0.3; 0.6)		2 [0.1]	4 [0.4]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)
	<b>IV</b>	12 [0.4]	6 [0.6]	12 [2.8]	30 [0.5]	0.6 (0.4; 0.8)		4 [0.1]	4 [0.4]	3 [0.5]	11 [0.2]	0.2 (0.1; 0.3)
	<b>X/NA</b>	7 [0.2]	9 [1.0]	2 [0.5]	18 [0.3]	0.3 (0.2; 0.5)		2 [0.1]	3 [0.3]	7 [1.1]	12 [0.2]	0.2 (0.1; 0.3)
Salivary glands C07-C08	<b>I</b>	9 [0.3]	1 [0.1]	2 [0.5]	12 [0.2]	0.2 (0.1; 0.3)		15 [0.5]	11 [1.1]	1 [0.2]	27 [0.5]	0.5 (0.3; 0.6)
	<b>II</b>	6 [0.2]	10 [1.1]	7 [1.6]	23 [0.4]	0.4 (0.3; 0.6)		5 [0.2]	6 [0.6]	1 [0.2]	13 [0.2]	0.2 (0.1; 0.3)
	<b>III</b>	2 [0.1]	5 [0.5]	3 [0.7]	10 [0.2]	0.2 (0.1; 0.3)		4 [0.1]	3 [0.3]	4 [0.6]	11 [0.2]	0.2 (0.1; 0.3)
	<b>IV</b>	6 [0.2]	13 [1.4]	8 [1.9]	27 [0.5]	0.5 (0.3; 0.7)		1 [0.0]	5 [0.5]	6 [0.9]	12 [0.2]	0.2 (0.1; 0.3)

Sub-locations	Stage	Males				Females					
		N[CR]				ESR2013 (95%CI)					
		15-59	60-74	75+	All ages	15-59	60-74	75+	All ages	ESR2013 (95%CI)	
	<b>X/NA</b>	3 [0.1]	7 [0.7]	5 [1.2]	15 [0.3]	0.3 (0.1; 0.4)	0 [0.0]	4 [0.4]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
<b>Other and ill-defined sites C14</b>	<b>I</b>	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	<b>II</b>	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	<b>III</b>	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	<b>IV</b>	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	<b>X/NA</b>	6 [0.2]	4 [0.4]	3 [0.7]	13 [0.2]	0.2 (0.1; 0.4)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Head & Neck cancer incidence trends: by region

2.1.1. *Head & Neck cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	1,953	1,856	1,781	1,982	1,955	1,969	1,838	2,027	1,967	1,997	2,019	1,964	2,015	2,008	1,996	2,076	1,836	1,952	1,943		
	<b>CR</b>	38.4	36.3	34.6	38.3	37.4	37.4	34.6	37.7	36.3	36.7	36.9	35.7	36.4	36.1	35.7	36.9	32.4	34.4	34.0		
	<b>ESR2013</b>	44.6	41.9	39.3	43.1	42.0	42.1	38.7	42.0	40.1	40.1	40.2	38.6	38.9	38.3	37.9	38.8	34.0	35.7	35.1	-1.1 (-1.4; -0.7)	2004-2022
Brussels	<b>N</b>	168	161	173	200	163	160	160	176	155	166	168	171	175	152	141	161	132	154	152		
	<b>CR</b>	35.0	33.3	35.3	40.3	32.3	31.0	30.4	32.4	28.0	29.6	29.6	29.9	30.2	26.1	24.0	27.2	22.1	25.7	25.3		
	<b>ESR2013</b>	46.4	45.0	48.6	55.4	45.2	44.2	43.1	47.5	41.2	42.3	44.1	43.9	43.9	39.1	34.2	39.7	32.3	38.3	35.5	-1.8 (-2.5; -1.1)	2004-2022
Flanders	<b>N</b>	1,062	969	974	1,017	1,022	1,055	1,003	1,080	1,058	1,123	1,113	1,073	1,081	1,110	1,127	1,181	1,053	1,090	1,107		
	<b>CR</b>	35.8	32.5	32.5	33.7	33.6	34.4	32.5	34.7	33.7	35.6	35.2	33.7	33.8	34.5	34.8	36.2	32.1	33.1	33.4		
	<b>ESR2013</b>	40.8	36.5	35.7	36.8	36.4	37.6	35.0	37.3	35.7	37.1	36.4	34.5	34.3	34.5	35.1	36.1	32.0	32.6	32.6	-0.8 (-1.1; -0.5)	2004-2022
Wallonia	<b>N</b>	723	726	634	765	770	754	675	771	754	708	738	720	759	746	728	734	651	708	684		
	<b>CR</b>	44.1	44.1	38.3	45.9	45.9	44.7	39.7	45.0	43.7	40.8	42.4	41.1	43.2	42.3	41.1	41.3	36.5	39.7	38.2		
	<b>ESR2013</b>	51.5	51.5	43.2	51.9	52.2	50.2	44.8	49.5	48.1	45.0	46.2	44.9	46.5	45.7	44.0	43.6	38.1	41.3	39.8	-1.3 (-1.8; -0.8)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Head & Neck cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	557	560	532	548	587	637	617	667	694	652	688	739	697	703	760	713	711	838	778		
	<b>CR</b>	10.5	10.5	9.9	10.1	10.8	11.6	11.2	12.0	12.3	11.5	12.1	13.0	12.2	12.2	13.2	12.3	12.2	14.3	13.2		
	<b>ESR2013</b>	10.9	10.9	10.3	10.4	11.0	12.0	11.4	12.1	12.5	11.6	12.2	12.9	12.0	11.9	12.8	11.9	11.8	13.8	12.7	1.0 (0.6; 1.5)	2004-2022
Brussels	<b>N</b>	61	67	71	51	56	66	66	70	72	54	54	71	62	69	79	59	50	66	58		
	<b>CR</b>	11.7	12.8	13.4	9.5	10.3	12.0	11.7	12.1	12.3	9.1	9.0	11.8	10.2	11.3	12.9	9.6	8.1	10.6	9.3		
	<b>ESR2013</b>	13.4	14.8	16.1	11.4	12.4	14.6	14.3	14.5	15.2	10.9	11.3	14.2	12.3	14.1	16.3	11.7	10.2	13.1	11.8	-0.8 (-2.0; 0.3)	2004-2022
Flanders	<b>N</b>	268	286	248	270	289	307	310	335	358	365	347	389	368	353	410	396	403	426	435		
	<b>CR</b>	8.8	9.3	8.0	8.7	9.3	9.8	9.8	10.5	11.1	11.3	10.7	11.9	11.2	10.7	12.4	11.9	12.0	12.7	12.9		
	<b>ESR2013</b>	9.0	9.6	8.2	8.7	9.1	9.8	9.8	10.3	10.8	11.0	10.3	11.4	10.6	9.9	11.5	11.1	11.1	11.7	11.8	1.6 (1.1; 2.1)	2004-2022
Wallonia	<b>N</b>	228	207	213	227	242	264	241	262	264	233	287	279	267	281	271	258	258	346	285		
	<b>CR</b>	13.1	11.8	12.1	12.8	13.6	14.8	13.4	14.5	14.5	12.7	15.6	15.2	14.5	15.2	14.6	13.9	13.8	18.6	15.2		
	<b>ESR2013</b>	13.7	12.5	12.7	13.3	14.2	15.3	13.6	14.8	14.9	13.0	15.7	15.2	14.2	15.2	14.2	13.5	13.4	17.8	14.6	0.7 (0.0; 1.4)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Head & Neck cancer incidence trends: by tumour stage

2.2.3. Head & Neck cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>I</b>	<b>N</b>	390	490	428	489	450			162	210	197	238	203		
	<b>CR</b>	7.0	8.7	7.6	8.6	7.9			2.8	3.6	3.4	4.1	3.5		
	<b>ESR2013</b>	7.5	9.2	8.0	9.0	8.1	2.0 (1.1; 2.9)	2004-2022	2.7	3.5	3.3	3.9	3.4	5.7 (4.5; 6.8)	2004-2022
													10.0 (6.8; 13.2)	2004-2011	
													0.9 (-3.5; 5.6)	2012-2015	
													4.2 (1.2; 7.3)	2016-2022	
<b>II</b>	<b>N</b>	269	290	257	299	311			123	114	103	126	132		
	<b>CR</b>	4.8	5.2	4.5	5.3	5.4			2.1	2.0	1.8	2.2	2.2		
	<b>ESR2013</b>	5.1	5.5	4.7	5.5	5.7	1.1 (0.4; 1.8)	2004-2022	2.1	1.9	1.7	2.1	2.2	3.1 (2.3; 3.8)	2004-2022
<b>III</b>	<b>N</b>	325	298	318	305	320			133	99	111	142	118		
	<b>CR</b>	5.8	5.3	5.6	5.4	5.6			2.3	1.7	1.9	2.4	2.0		
	<b>ESR2013</b>	6.2	5.6	5.9	5.6	5.8	0.4 (-0.3; 1.1)	2004-2022	2.2	1.6	1.9	2.3	1.9	3.0 (2.0; 4.1)	2004-2022
<b>IV</b>	<b>N</b>	836	840	742	723	732			281	238	241	277	275		
	<b>CR</b>	14.9	14.9	13.1	12.7	12.8			4.9	4.1	4.1	4.7	4.7		
	<b>ESR2013</b>	15.7	15.6	13.6	13.2	13.2	-0.1 (-0.5; 0.3)	2004-2022	4.7	3.9	3.9	4.5	4.4	2.2 (1.5; 3.0)	2004-2022
							2.1 (1.3; 3.0)	2004-2014						5.0 (3.5; 6.5)	2004-2014
						-2.8 (-3.8; -1.7)	2015-2022						-1.1 (-2.9; 0.7)	2015-2022	
<b>X/NA</b>	<b>N</b>	176	158	91	136	130			61	52	59	55	50		
	<b>CR</b>	3.1	2.8	1.6	2.4	2.3			1.1	0.9	1.0	0.9	0.9		
	<b>ESR2013</b>	3.4	3.0	1.7	2.4	2.4	-10.2 (-11.3; -9.0)	2004-2022	1.0	0.9	1.0	0.9	0.8	-8.9 (-9.6; -8.2)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.3. Head & Neck cancer incidence trends: by age group

2.3.4. Head & Neck cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
<b>15-59</b>	<b>N</b>	953	880	835	897	856	847	742	816	801	780	716	701	687	655	626	633	530	545	495			
	<b>CR</b>	29.8	27.4	25.9	27.7	26.3	25.9	22.6	24.7	24.1	23.5	21.5	21.1	20.6	19.6	18.8	19.0	15.9	16.3	14.8			
	<b>ESR2013</b>		31.8	29.0	26.9	28.8	27.3	26.7	23.2	25.2	24.4	23.6	21.4	20.8	20.2	19.2	18.3	18.4	15.4	15.9	14.4	-3.9 (-4.3; -3.6)	2004-2022
<b>60-74</b>	<b>N</b>	722	706	685	809	795	796	765	896	865	895	958	921	1,001	1,014	1,017	1,046	932	1,022	1,029			
	<b>CR</b>	106.1	103.1	99.7	115.6	111.6	109.5	103.2	118.5	112.4	114.2	120.2	113.3	120.2	118.4	115.7	116.4	101.6	109.4	108.8			
	<b>ESR2013</b>		106.4	103.2	99.7	114.9	110.3	109.8	103.0	118.2	111.8	113.2	118.6	112.8	120.3	118.1	115.9	116.4	102.0	109.7	108.8	0.2 (-0.2; 0.6)	2004-2022
<b>75+</b>	<b>N</b>	275	269	259	274	303	324	328	312	299	321	342	338	323	337	352	395	374	384	418			
	<b>CR</b>	93.8	88.9	82.5	84.1	90.0	93.8	92.6	86.4	81.0	85.4	89.2	86.3	81.8	85.4	88.6	97.8	90.4	92.3	96.9			
	<b>ESR2013</b>		92.8	87.8	78.1	80.9	87.7	92.7	89.8	85.6	81.7	84.1	88.7	86.2	79.8	84.0	89.1	97.3	90.6	92.4	96.8	0.4 (-0.1; 0.9)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



2.3.5. Head & Neck cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
<b>15-59</b>	<b>N</b>	245	236	240	254	257	275	257	262	270	232	251	249	197	213	217	206	196	238	213			
	<b>CR</b>	7.8	7.5	7.6	8.0	8.0	8.5	7.9	8.0	8.3	7.1	7.6	7.6	6.0	6.5	6.6	6.3	6.0	7.2	6.5			
	<b>ESR2013</b>	8.1	7.8	7.8	8.2	8.2	8.7	8.1	8.1	8.3	7.1	7.6	7.5	5.9	6.3	6.4	6.1	5.9	7.1	6.3	-1.8 (-2.5; -1.1)	2004-2022	
<b>60-74</b>	<b>N</b>	187	197	185	177	196	237	224	250	285	271	294	325	325	310	342	322	325	389	366			
	<b>CR</b>	24.1	25.4	24.0	22.7	24.9	29.6	27.7	30.4	34.2	32.0	34.3	37.3	36.4	33.8	36.4	33.6	33.3	39.1	36.4			
	<b>ESR2013</b>	24.1	25.6	24.3	22.7	24.8	29.7	27.6	30.3	33.9	31.9	34.1	37.2	36.4	33.8	36.3	33.6	33.2	39.2	36.5	2.6 (2.0; 3.2)	2004-2022	
																					4.1 (3.0; 5.1)	2004-2015	
																						0.2 (-1.4; 2.0)	2016-2022
<b>75+</b>	<b>N</b>	124	127	104	114	133	122	134	152	138	147	142	163	173	180	199	184	187	209	198			
	<b>CR</b>	23.9	23.9	19.1	20.5	23.3	21.1	22.8	25.6	23.0	24.3	23.3	26.4	28.1	29.4	32.6	30.0	30.1	33.8	31.2			
	<b>ESR2013</b>	24.3	23.9	19.1	20.2	23.5	21.4	23.2	25.5	22.8	24.1	23.6	26.1	28.0	29.7	33.6	30.8	31.4	34.7	32.7	2.6 (1.7; 3.4)	2004-2022	
																					0.0 (-2.8; 2.9)	2004-2010	
																					3.2 (-0.4; 7.1)	2011-2014	
																					4.2 (2.1; 6.2)	2015-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



#### 3.1. Head & Neck cancer prevalence: by region

3.1.1. *Head & Neck cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	<b>N</b>	1,677	6,132	9,527	11,588	667	2,571	3,994	4,934
	<b>CR</b>	29.1	106.4	165.4	201	11.2	43.3	67.3	83
	<b>ESR2013</b>	29.8	109.4	170.6	208.3	10.8	41.4	64.1	79.0
Brussels	<b>N</b>	132	458	729	880	51	214	342	430
	<b>CR</b>	21.7	75.3	119.8	144.7	8.1	33.8	54.0	67.9
	<b>ESR2013</b>	30.2	107.8	175.8	215.4	10.3	42.6	67.8	84.7
Flanders	<b>N</b>	971	3,587	5,600	6,832	386	1,421	2,206	2,695
	<b>CR</b>	29.0	107.0	167.0	203.8	11.3	41.5	64.5	78.7
	<b>ESR2013</b>	28.1	104.2	162.9	199.1	10.4	38.1	58.9	71.8
Wallonia	<b>N</b>	574	2,087	3,198	3,876	230	936	1,446	1,809
	<b>CR</b>	31.9	115.9	177.6	215.2	12.2	49.8	76.9	96.2
	<b>ESR2013</b>	32.7	119.0	183.6	224.1	11.7	47.3	72.7	90.7



### 4.1. Head & Neck cancer survival: by region

4.1.1. *Head & Neck cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022*

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total		25,832	79.9% (79.4%; 80.4%)	63.6% (62.9%; 64.3%)	56.0% (55.2%; 56.8%)	42.1% (40.1%; 44.2%)
Males						
Belgium	15-59	6,107	84.9% (84.0%; 85.8%)	66.7% (65.4%; 67.9%)	57.8% (56.5%; 59.2%)	45.3% (43.4%; 47.2%)
	60-74	9,388	78.7% (77.9%; 79.6%)	61.3% (60.3%; 62.4%)	52.9% (51.7%; 54.1%)	36.7% (34.8%; 38.8%)
	75+	3,492	72.9% (71.3%; 74.7%)	56.9% (54.6%; 59.2%)	51.5% (48.6%; 54.7%)	35.8% (27.5%; 46.5%)
Brussels	15-59	548	83.6% (80.5%; 86.8%)	66.5% (62.5%; 70.8%)	59.2% (54.7%; 64.0%)	48.0% (41.8%; 55.2%)
	60-74	676	74.4% (71.1%; 77.9%)	55.6% (51.6%; 59.9%)	46.5% (42.2%; 51.3%)	33.5% (26.7%; 42.1%)
	75+	284	72.8% (67.1%; 79.1%)	60.7% (53.3%; 69.3%)	55.8% (46.4%; 67.2%)	46.4% (29.8%; 72.3%)
Flanders	15-59	3,091	86.5% (85.2%; 87.7%)	70.6% (68.9%; 72.3%)	62.1% (60.2%; 64.0%)	50.0% (47.5%; 52.7%)
	60-74	5,293	80.4% (79.3%; 81.5%)	63.5% (62.1%; 64.9%)	55.1% (53.5%; 56.7%)	39.4% (36.8%; 42.1%)
	75+	2,245	74.8% (72.7%; 76.9%)	59.4% (56.6%; 62.2%)	52.6% (48.9%; 56.7%)	32.3% (22.4%; 46.6%)
Wallonia	15-59	2,469	83.2% (81.7%; 84.7%)	61.9% (59.9%; 63.9%)	52.2% (50.1%; 54.5%)	38.9% (36.0%; 42.0%)
	60-74	3,420	77.0% (75.5%; 78.5%)	59.2% (57.4%; 61.1%)	50.7% (48.7%; 52.8%)	33.2% (30.0%; 36.8%)
	75+	964	68.7% (65.4%; 72.1%)	49.8% (45.6%; 54.3%)	47.6% (42.4%; 53.4%)	41.0% (28.1%; 59.7%)
Females						

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Belgium	15-59	2,128	89.0% (87.7%; 90.4%)	77.0% (75.1%; 78.8%)	70.5% (68.4%; 72.6%)	58.5% (55.5%; 61.8%)
	60-74	3,137	81.5% (80.1%; 82.9%)	66.4% (64.7%; 68.3%)	58.5% (56.5%; 60.6%)	44.9% (41.8%; 48.2%)
	75+	1,733	68.8% (66.4%; 71.3%)	56.5% (53.5%; 59.7%)	53.1% (49.3%; 57.2%)	44.8% (29.8%; 67.2%)
Brussels	15-59	206	91.8% (88.1%; 95.7%)	79.2% (73.6%; 85.2%)	75.8% (69.7%; 82.4%)	70.8% (61.2%; 82.0%)
	60-74	253	80.5% (75.6%; 85.7%)	64.6% (58.5%; 71.3%)	58.7% (52.0%; 66.2%)	40.9% (31.1%; 53.9%)
	75+	149	64.0% (56.0%; 73.0%)	49.5% (40.2%; 61.0%)	40.3% (29.5%; 55.0%)	8.7% (2.6%; 29.2%)
Flanders	15-59	1,062	90.9% (89.1%; 92.7%)	80.4% (78.0%; 82.9%)	73.7% (70.8%; 76.7%)	61.3% (57.0%; 65.9%)
	60-74	1,639	83.4% (81.6%; 85.3%)	69.1% (66.7%; 71.5%)	61.2% (58.5%; 64.0%)	46.4% (41.9%; 51.2%)
	75+	1,038	70.9% (67.8%; 74.1%)	58.3% (54.4%; 62.4%)	52.8% (48.0%; 58.1%)	56.3% (41.7%; 76.1%)
Wallonia	15-59	860	86.0% (83.7%; 88.4%)	72.1% (69.1%; 75.3%)	65.2% (61.8%; 68.8%)	52.2% (47.5%; 57.4%)
	60-74	1,245	79.2% (76.9%; 81.6%)	63.4% (60.6%; 66.3%)	55.0% (51.8%; 58.3%)	43.4% (39.0%; 48.4%)
	75+	546	66.3% (62.0%; 70.9%)	55.1% (49.8%; 61.0%)	57.1% (50.3%; 64.7%)	40.7% (17.6%; 94.0%)

## 4.2. Head & Neck cancer survival: by sub-location and tumour stage

### 4.2.2. Head & Neck cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022								
Sub-location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total (C00-C14, C30-C32)</b>		25,832	79.9% (79.4%; 80.4%)	69.8% (69.2%; 70.4%)	63.6% (62.9%; 64.3%)	59.2% (58.5%; 60.0%)	56.0% (55.2%; 56.8%)	42.1% (40.1%; 44.2%)
<b>Males</b>								
<b>Lip (C00)</b>	<b>I</b>	136	99.3% (95.5%; 103.3%)	97.2% (91.0%; 103.9%)	94.4% (86.2%; 103.5%)	94.2% (84.7%; 104.8%)	91.7% (80.2%; 104.9%)	53.5% (21.2%; 135.0%)
	<b>II</b>	31	N<50	N<50	N<50	N<50	N<50	N<50
	<b>III</b>	19	N<50	N<50	N<50	N<50	N<50	N<50
	<b>IV</b>	18	N<50	N<50	N<50	N<50	N<50	N<50
	<b>X/NA</b>	124	96.9% (92.1%; 101.9%)	94.1% (87.3%; 101.3%)	88.1% (79.6%; 97.6%)	83.2% (72.7%; 95.2%)	82.9% (71.7%; 95.8%)	86.6% (66.8%; 112.4%)
<b>Oral cavity (C02-C05.0, C06)</b>	<b>I</b>	780	95.2% (93.4%; 97.0%)	87.9% (85.3%; 90.7%)	83.2% (80.0%; 86.5%)	78.6% (75.0%; 82.5%)	74.7% (70.5%; 79.1%)	59.9% (52.7%; 68.0%)
	<b>II</b>	665	90.2% (87.8%; 92.8%)	80.9% (77.6%; 84.3%)	70.5% (66.6%; 74.6%)	65.1% (60.8%; 69.7%)	61.2% (56.6%; 66.2%)	43.9% (35.7%; 54.1%)
	<b>III</b>	598	81.0% (77.7%; 84.4%)	69.9% (66.1%; 74.0%)	62.2% (58.0%; 66.8%)	54.9% (50.3%; 60.0%)	50.8% (45.7%; 56.4%)	32.5% (24.6%; 43.0%)
	<b>IV</b>	1,624	69.2% (66.9%; 71.6%)	54.5% (52.0%; 57.1%)	46.3% (43.7%; 49.0%)	41.5% (38.8%; 44.3%)	37.2% (34.4%; 40.2%)	25.4% (21.1%; 30.6%)
	<b>X/NA</b>	699	80.4% (77.4%; 83.7%)	71.5% (67.9%; 75.3%)	65.7% (61.8%; 69.8%)	60.9% (56.6%; 65.4%)	59.1% (54.7%; 63.9%)	40.8% (33.4%; 49.9%)
<b>Pharynx (C01, C05.1-C05.9, C09-C13)</b>	<b>I</b>	851	92.3% (90.3%; 94.3%)	83.1% (80.3%; 86.0%)	77.1% (73.8%; 80.6%)	71.4% (67.5%; 75.4%)	67.5% (63.2%; 72.1%)	47.7% (39.5%; 57.7%)
	<b>II</b>	957	87.7% (85.5%; 90.0%)	78.0% (75.1%; 81.0%)	69.9% (66.6%; 73.4%)	64.6% (60.9%; 68.5%)	59.6% (55.6%; 63.8%)	41.2% (34.6%; 49.1%)
	<b>III</b>	1,291	82.1% (79.9%; 84.3%)	71.6% (69.0%; 74.3%)	65.5% (62.6%; 68.5%)	61.1% (58.0%; 64.4%)	57.8% (54.5%; 61.3%)	40.8% (34.8%; 47.8%)
	<b>IV</b>	4,273	66.8% (65.3%; 68.3%)	51.6% (50.1%; 53.2%)	43.2% (41.6%; 44.8%)	38.7% (37.1%; 40.3%)	34.4% (32.7%; 36.1%)	24.8% (22.7%; 27.2%)
	<b>X/NA</b>	845	70.3% (67.2%; 73.6%)	57.3% (53.9%; 60.9%)	50.2% (46.8%; 54.0%)	43.9% (40.4%; 47.8%)	41.0% (37.4%; 44.9%)	29.1% (24.7%; 34.2%)

Net Survival Probability, 2013-2022								
Sub-location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Oropharynx C01;C05.1- C05.9;C09-C10	I	718	92.6% (90.5%; 94.8%)	84.0% (81.0%; 87.2%)	79.1% (75.6%; 82.8%)	73.4% (69.2%; 77.8%)	69.8% (65.0%; 75.0%)	50.1% (40.3%; 62.2%)
	II	689	90.1% (87.7%; 92.7%)	80.6% (77.3%; 84.0%)	72.4% (68.6%; 76.5%)	66.2% (61.9%; 70.8%)	61.0% (56.3%; 66.1%)	44.6% (36.1%; 55.2%)
	III	821	82.0% (79.2%; 84.8%)	71.3% (68.1%; 74.8%)	65.8% (62.2%; 69.5%)	62.3% (58.5%; 66.3%)	57.5% (53.5%; 61.9%)	40.4% (31.6%; 51.6%)
	IV	2,540	68.5% (66.6%; 70.4%)	53.8% (51.9%; 55.9%)	46.3% (44.3%; 48.5%)	42.2% (40.1%; 44.4%)	37.6% (35.4%; 39.9%)	27.8% (24.9%; 30.9%)
	X/NA	629	73.0% (69.5%; 76.7%)	60.4% (56.4%; 64.5%)	53.0% (49.0%; 57.4%)	46.3% (42.2%; 50.9%)	44.2% (40.0%; 48.9%)	31.2% (26.1%; 37.4%)
Nasopharynx C11	I	29	N<50	N<50	N<50	N<50	N<50	N<50
	II	87	93.2% (87.6%; 99.2%)	90.9% (84.2%; 98.2%)	87.7% (79.7%; 96.6%)	84.8% (75.4%; 95.3%)	86.0% (76.5%; 96.7%)	66.4% (50.8%; 86.7%)
	III	143	90.3% (85.4%; 95.6%)	87.6% (81.9%; 93.6%)	82.0% (75.4%; 89.3%)	79.4% (72.2%; 87.3%)	80.3% (73.0%; 88.2%)	74.5% (64.6%; 86.0%)
	IV	156	77.6% (71.2%; 84.6%)	68.1% (60.9%; 76.1%)	59.8% (52.2%; 68.5%)	57.7% (49.8%; 66.8%)	52.7% (44.3%; 62.6%)	41.1% (29.7%; 57.0%)
	X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	I	106	89.8% (83.6%; 96.4%)	78.1% (69.9%; 87.4%)	64.1% (54.5%; 75.4%)	56.0% (46.0%; 68.1%)	51.8% (41.6%; 64.6%)	33.2% (20.6%; 53.7%)
	II	187	75.0% (68.7%; 81.8%)	61.1% (54.0%; 69.2%)	50.7% (43.2%; 59.4%)	47.4% (39.7%; 56.5%)	39.4% (31.5%; 49.2%)	20.4% (12.1%; 34.4%)
	III	328	78.8% (74.3%; 83.6%)	65.3% (60.0%; 71.1%)	57.8% (52.1%; 64.1%)	50.5% (44.3%; 57.6%)	48.7% (42.3%; 56.1%)	27.6% (20.0%; 38.1%)
	IV	1,597	63.0% (60.6%; 65.5%)	46.3% (43.8%; 48.9%)	36.4% (34.0%; 39.0%)	31.1% (28.7%; 33.7%)	27.3% (24.8%; 29.9%)	18.0% (15.0%; 21.5%)
	X/NA	180	60.5% (53.6%; 68.2%)	48.1% (41.1%; 56.3%)	41.0% (34.1%; 49.3%)	35.8% (28.9%; 44.2%)	31.5% (24.7%; 40.1%)	21.7% (13.9%; 33.7%)
<b>Larynx (C32)</b>	I	1,540	97.5% (96.3%; 98.7%)	96.1% (94.4%; 97.8%)	93.1% (90.9%; 95.4%)	91.4% (88.5%; 94.5%)	89.9% (86.5%; 93.5%)	67.9% (56.0%; 82.4%)
	II	765	90.3% (87.9%; 92.7%)	82.9% (79.8%; 86.1%)	77.4% (73.8%; 81.2%)	71.5% (67.5%; 75.8%)	68.5% (64.0%; 73.3%)	49.9% (42.0%; 59.1%)
	III	733	81.4% (78.4%; 84.5%)	72.4% (68.9%; 76.2%)	65.1% (61.2%; 69.3%)	59.0% (54.7%; 63.5%)	54.5% (50.0%; 59.5%)	31.3% (23.3%; 42.2%)
	IV	1,164	70.3% (67.7%; 73.1%)	56.7% (53.7%; 59.8%)	49.0% (45.9%; 52.3%)	43.3% (40.1%; 46.7%)	39.3% (36.0%; 42.9%)	24.0% (19.7%; 29.1%)
	X/NA	611	82.0% (78.8%; 85.4%)	75.9% (72.1%; 79.9%)	70.4% (66.2%; 75.0%)	65.8% (61.1%; 70.9%)	63.5% (58.4%; 68.9%)	45.6% (37.6%; 55.3%)

Net Survival Probability, 2013-2022								
Sub-location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Nasal cavity and paranasal sinuses (C30-C31)</b>	I	87	94.6% (89.0%; 100.6%)	86.8% (78.4%; 96.1%)	82.3% (72.3%; 93.7%)	82.3% (71.7%; 94.5%)	84.5% (73.6%; 97.0%)	71.6% (50.7%; 101.1%)
	II	112	99.2% (95.2%; 103.2%)	95.9% (89.6%; 102.6%)	91.9% (83.2%; 101.5%)	86.6% (75.6%; 99.2%)	90.8% (78.9%; 104.6%)	82.5% (55.3%; 123.2%)
	III	102	87.6% (80.5%; 95.3%)	79.4% (70.5%; 89.5%)	69.9% (59.0%; 82.7%)	66.9% (55.2%; 81.1%)	66.7% (54.3%; 82.0%)	44.1% (26.0%; 74.7%)
	IV	312	68.5% (63.2%; 74.1%)	51.4% (45.7%; 57.8%)	43.5% (37.7%; 50.2%)	40.4% (34.5%; 47.4%)	38.9% (32.8%; 46.2%)	32.2% (21.1%; 49.0%)
	X/NA	348	83.3% (79.1%; 87.8%)	69.5% (64.2%; 75.2%)	65.3% (59.5%; 71.6%)	60.1% (53.9%; 67.0%)	57.3% (50.7%; 64.8%)	47.3% (33.3%; 67.2%)
<b>Salivary glands (C07-C08)</b>	I	73	102.0% (99.3%; 104.7%)	101.6% (95.9%; 107.6%)	105.5% (98.8%; 112.6%)	114.2% (107.0%; 121.8%)	104.2% (84.7%; 128.2%)	79.3% (41.4%; 151.8%)
	II	106	95.1% (89.9%; 100.6%)	91.5% (84.5%; 99.1%)	83.6% (74.4%; 93.9%)	84.4% (74.6%; 95.4%)	80.2% (68.4%; 94.0%)	57.9% (38.4%; 87.3%)
	III	82	89.0% (81.0%; 97.8%)	84.6% (74.5%; 96.1%)	77.1% (63.8%; 93.1%)	75.8% (61.2%; 93.9%)	59.9% (37.6%; 95.7%)	44.7% (23.6%; 84.5%)
	IV	220	67.9% (61.6%; 75.0%)	49.4% (42.5%; 57.4%)	41.3% (34.3%; 49.8%)	33.5% (26.4%; 42.6%)	26.6% (19.0%; 37.2%)	26.2% (16.6%; 41.6%)
	X/NA	332	89.9% (86.2%; 93.9%)	78.0% (72.9%; 83.5%)	68.9% (63.0%; 75.4%)	66.7% (60.5%; 73.6%)	65.9% (59.4%; 73.1%)	57.2% (45.8%; 71.5%)
<b>Other and ill-defined sites (C14)</b>	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	146	53.4% (45.8%; 62.3%)	42.5% (35.0%; 51.8%)	36.1% (28.7%; 45.4%)	29.9% (22.8%; 39.2%)	28.6% (21.4%; 38.1%)	8.5% (3.0%; 24.6%)
<b>Females</b>								
<b>Lip (C00)</b>	I	64	101.4% (96.9%; 106.1%)	102.2% (94.4%; 110.6%)	92.1% (78.6%; 107.9%)	87.9% (72.8%; 106.0%)	92.7% (76.8%; 111.9%)	126.6% (90.2%; 177.7%)
	II	23	N<50	N<50	N<50	N<50	N<50	N<50
	III	10	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	60	98.2% (90.7%; 106.2%)	87.6% (75.5%; 101.5%)	86.6% (72.5%; 103.4%)	80.5% (63.5%; 102.0%)	80.7% (61.5%; 105.8%)	57.3% (26.3%; 124.9%)

Net Survival Probability, 2013-2022								
Sub-location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Oral cavity (C02-C05.0, C06)</b>	<b>I</b>	521	96.0% (93.9%; 98.2%)	92.1% (89.2%; 95.1%)	89.9% (86.3%; 93.6%)	85.6% (81.3%; 90.1%)	82.3% (77.4%; 87.4%)	72.1% (59.1%; 88.0%)
	<b>II</b>	390	90.8% (87.5%; 94.2%)	85.3% (81.1%; 89.8%)	79.9% (74.9%; 85.4%)	75.7% (69.5%; 82.4%)	75.7% (69.1%; 82.9%)	55.5% (25.0%; 122.9%)
	<b>III</b>	290	82.1% (77.5%; 87.0%)	69.3% (63.7%; 75.3%)	64.8% (58.8%; 71.4%)	58.4% (51.7%; 66.0%)	58.2% (51.1%; 66.2%)	56.5% (44.6%; 71.6%)
	<b>IV</b>	813	62.7% (59.3%; 66.3%)	47.7% (44.2%; 51.5%)	42.6% (39.0%; 46.5%)	40.1% (36.4%; 44.1%)	36.2% (32.4%; 40.5%)	24.2% (16.5%; 35.6%)
	<b>X/NA</b>	441	82.8% (79.1%; 86.8%)	73.3% (68.8%; 78.1%)	68.1% (63.2%; 73.5%)	64.5% (59.3%; 70.2%)	62.7% (57.1%; 68.8%)	56.2% (47.0%; 67.4%)
<b>Pharynx (C01, C05.1-C05.9, C09-C13)</b>	<b>I</b>	380	91.0% (88.0%; 94.2%)	87.7% (84.0%; 91.5%)	81.0% (76.4%; 85.9%)	75.9% (70.6%; 81.6%)	73.6% (67.7%; 80.0%)	56.0% (43.6%; 71.9%)
	<b>II</b>	403	90.3% (87.2%; 93.5%)	80.8% (76.7%; 85.1%)	78.0% (73.5%; 82.8%)	72.6% (67.5%; 78.1%)	70.2% (64.7%; 76.1%)	51.3% (42.0%; 62.6%)
	<b>III</b>	450	80.4% (76.7%; 84.4%)	71.6% (67.3%; 76.2%)	64.7% (60.0%; 69.8%)	60.4% (55.4%; 65.9%)	57.3% (52.1%; 63.1%)	43.5% (34.3%; 55.2%)
	<b>IV</b>	1,168	66.7% (64.0%; 69.5%)	53.9% (51.0%; 57.0%)	46.6% (43.7%; 49.8%)	42.7% (39.7%; 45.9%)	38.4% (35.4%; 41.7%)	27.5% (23.0%; 33.0%)
	<b>X/NA</b>	311	76.6% (71.8%; 81.7%)	66.2% (60.8%; 72.0%)	64.4% (58.9%; 70.5%)	57.3% (51.3%; 63.9%)	54.8% (48.8%; 61.7%)	35.8% (28.2%; 45.5%)
Oropharynx C01;C05.1- C05.9;C09-C10	<b>I</b>	329	91.9% (88.8%; 95.2%)	88.2% (84.3%; 92.3%)	82.4% (77.5%; 87.6%)	77.8% (72.2%; 83.9%)	75.6% (69.3%; 82.4%)	58.4% (44.8%; 76.2%)
	<b>II</b>	306	90.2% (86.7%; 93.9%)	80.6% (75.9%; 85.6%)	77.5% (72.3%; 83.0%)	71.2% (65.2%; 77.7%)	68.4% (62.0%; 75.5%)	46.3% (36.3%; 59.1%)
	<b>III</b>	326	81.4% (77.0%; 86.0%)	72.8% (67.7%; 78.1%)	67.3% (61.9%; 73.2%)	63.8% (58.0%; 70.2%)	60.3% (54.2%; 67.1%)	45.0% (33.6%; 60.3%)
	<b>IV</b>	843	69.2% (66.1%; 72.4%)	55.6% (52.2%; 59.2%)	48.6% (45.2%; 52.3%)	44.7% (41.2%; 48.5%)	41.0% (37.5%; 44.9%)	31.0% (25.3%; 37.9%)
	<b>X/NA</b>	260	77.6% (72.4%; 83.1%)	66.1% (60.2%; 72.5%)	65.9% (60.0%; 72.5%)	61.4% (55.0%; 68.5%)	59.8% (53.3%; 67.2%)	40.6% (32.2%; 51.1%)
Nasopharynx C11	<b>I</b>	10	N<50	N<50	N<50	N<50	N<50	N<50
	<b>II</b>	47	N<50	N<50	N<50	N<50	N<50	N<50
	<b>III</b>	48	N<50	N<50	N<50	N<50	N<50	N<50
	<b>IV</b>	61	72.5% (61.9%; 84.9%)	69.6% (58.7%; 82.5%)	64.2% (52.8%; 78.2%)	64.7% (53.1%; 78.7%)	61.9% (49.8%; 76.9%)	52.0% (37.3%; 72.5%)
	<b>X/NA</b>	16	N<50	N<50	N<50	N<50	N<50	N<50



Net Survival Probability, 2013-2022								
Sub-location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Hypopharynx C12-C13	I	42	N<50	N<50	N<50	N<50	N<50	N<50
	II	51	81.4% (70.9%; 93.5%)	65.5% (53.1%; 80.9%)	64.0% (51.3%; 79.8%)	61.4% (48.1%; 78.3%)	57.8% (43.7%; 76.5%)	56.4% (39.3%; 81.1%)
	III	77	72.4% (62.9%; 83.3%)	62.6% (52.4%; 74.9%)	46.9% (36.4%; 60.5%)	36.0% (25.6%; 50.6%)	34.8% (24.3%; 49.8%)	22.1% (11.3%; 43.0%)
	IV	265	57.2% (51.5%; 63.6%)	44.8% (39.0%; 51.5%)	35.9% (30.2%; 42.7%)	30.8% (25.2%; 37.6%)	24.0% (18.6%; 30.9%)	10.5% (6.0%; 18.6%)
	X/NA	35	N<50	N<50	N<50	N<50	N<50	N<50
Larynx (C32)	I	257	97.0% (94.2%; 99.9%)	96.3% (92.8%; 100.0%)	94.2% (89.7%; 98.9%)	92.6% (87.2%; 98.4%)	95.3% (89.6%; 101.4%)	101.9% (89.3%; 116.3%)
	II	139	90.5% (85.4%; 95.9%)	81.2% (74.5%; 88.6%)	77.1% (69.6%; 85.5%)	70.1% (61.5%; 79.8%)	66.0% (57.0%; 76.5%)	46.2% (33.7%; 63.3%)
	III	143	81.7% (75.1%; 88.8%)	71.4% (63.9%; 79.9%)	62.2% (53.9%; 71.7%)	59.6% (50.8%; 69.9%)	50.0% (40.6%; 61.6%)	38.0% (25.4%; 56.7%)
	IV	216	70.5% (64.6%; 77.0%)	56.8% (50.3%; 64.1%)	48.9% (42.3%; 56.6%)	44.3% (37.6%; 52.3%)	42.8% (35.9%; 50.9%)	25.1% (17.2%; 36.8%)
	X/NA	119	83.8% (77.1%; 91.1%)	78.5% (70.8%; 87.0%)	70.0% (61.4%; 79.9%)	65.3% (55.6%; 76.7%)	60.2% (50.2%; 72.2%)	55.9% (42.7%; 73.1%)
Nasal cavity and paranasal sinuses (C30- C31)	I	47	N<50	N<50	N<50	N<50	N<50	N<50
	II	20	N<50	N<50	N<50	N<50	N<50	N<50
	III	30	N<50	N<50	N<50	N<50	N<50	N<50
	IV	115	58.8% (50.2%; 68.9%)	50.1% (41.1%; 61.2%)	44.1% (34.9%; 55.7%)	37.9% (28.7%; 50.1%)	37.2% (27.8%; 49.7%)	17.5% (8.2%; 37.4%)
	X/NA	155	83.9% (77.9%; 90.5%)	72.3% (64.9%; 80.6%)	69.0% (61.0%; 78.0%)	66.4% (58.0%; 76.1%)	62.0% (53.0%; 72.6%)	48.1% (34.5%; 66.8%)
Salivary glands (C07-C08)	I	107	100.2% (98.4%; 102.1%)	99.5% (96.2%; 102.9%)	98.5% (93.6%; 103.7%)	97.2% (90.5%; 104.5%)	94.7% (85.1%; 105.3%)	114.2% (99.2%; 131.5%)
	II	85	99.9% (96.6%; 103.4%)	101.6% (97.4%; 105.9%)	102.0% (96.0%; 108.3%)	104.8% (97.8%; 112.3%)	111.6% (104.1%; 119.6%)	88.4% (58.2%; 134.1%)
	III	54	91.8% (83.5%; 100.8%)	88.5% (78.1%; 100.2%)	88.7% (76.8%; 102.5%)	88.6% (74.9%; 104.8%)	81.9% (66.6%; 100.9%)	51.7% (20.7%; 129.1%)
	IV	116	65.9% (57.2%; 76.0%)	59.6% (50.2%; 70.9%)	62.2% (52.2%; 74.2%)	58.9% (47.9%; 72.4%)	52.1% (40.1%; 67.7%)	25.6% (12.2%; 54.0%)
	X/NA	237	91.9% (88.0%; 96.1%)	91.1% (86.4%; 95.9%)	88.2% (82.8%; 94.0%)	86.8% (80.3%; 93.8%)	87.6% (80.7%; 95.1%)	82.1% (66.1%; 101.9%)

Net Survival Probability, 2013-2022								
Sub-location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Other and ill-defined sites (C14)</b>	<b>I</b>	0	N<50	N<50	N<50	N<50	N<50	N<50
	<b>II</b>	0	N<50	N<50	N<50	N<50	N<50	N<50
	<b>III</b>	0	N<50	N<50	N<50	N<50	N<50	N<50
	<b>IV</b>	0	N<50	N<50	N<50	N<50	N<50	N<50
	<b>X/NA</b>	47	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.3. Head & Neck cancer survival by sub-location, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022								
Sub-location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total (C00-C14, C30-C32)</b>		25,832	79.9% (79.4%; 80.4%)	69.8% (69.2%; 70.4%)	63.6% (62.9%; 64.3%)	59.2% (58.5%; 60.0%)	56.0% (55.2%; 56.8%)	42.1% (40.1%; 44.2%)
<b>Males</b>								
<b>Lip (C00)</b>	<b>I</b>	189	100.2% (97.1%; 103.3%)	98.1% (93.0%; 103.5%)	96.4% (89.9%; 103.4%)	94.0% (85.8%; 103.1%)	92.4% (82.8%; 103.2%)	81.4% (48.3%; 137.2%)
	<b>II</b>	50	95.0% (87.1%; 103.5%)	91.0% (80.6%; 102.8%)	83.5% (70.6%; 98.8%)	86.9% (73.4%; 102.8%)	88.7% (74.2%; 106.1%)	95.3% (71.2%; 127.6%)
	<b>III</b>	15	N<50	N<50	N<50	N<50	N<50	N<50
	<b>IV</b>	14	N<50	N<50	N<50	N<50	N<50	N<50
	<b>X/NA</b>	60	87.3% (78.0%; 97.7%)	75.8% (63.9%; 89.9%)	68.1% (54.4%; 85.4%)	66.0% (50.9%; 85.4%)	67.3% (51.5%; 87.9%)	55.6% (34.7%; 89.0%)
<b>Oral cavity (C02-C05.0, C06)</b>	<b>I</b>	957	97.6% (96.3%; 98.9%)	93.3% (91.3%; 95.4%)	88.7% (86.0%; 91.4%)	84.5% (81.4%; 87.8%)	81.0% (77.2%; 84.9%)	57.3% (48.6%; 67.5%)
	<b>II</b>	567	91.4% (88.8%; 94.0%)	85.1% (81.8%; 88.6%)	77.2% (73.1%; 81.5%)	70.1% (65.4%; 75.3%)	65.5% (60.3%; 71.1%)	47.3% (38.4%; 58.2%)
	<b>III</b>	543	88.3% (85.4%; 91.3%)	77.6% (73.8%; 81.5%)	68.2% (63.9%; 72.9%)	63.4% (58.5%; 68.6%)	58.8% (53.5%; 64.6%)	42.7% (33.7%; 54.1%)
	<b>IV</b>	1,052	80.6% (78.1%; 83.2%)	64.2% (61.2%; 67.4%)	55.0% (51.7%; 58.4%)	48.0% (44.6%; 51.6%)	44.1% (40.6%; 47.9%)	30.8% (24.9%; 38.1%)
	<b>X/NA</b>	1,238	58.7% (56.0%; 61.6%)	44.1% (41.3%; 47.1%)	37.2% (34.4%; 40.3%)	33.5% (30.6%; 36.6%)	30.9% (28.0%; 34.2%)	21.6% (17.9%; 26.2%)
<b>Pharynx (C01, C05.1-C05.9, C09-C13)</b>	<b>I</b>	553	94.9% (92.8%; 97.1%)	86.9% (83.8%; 90.3%)	80.0% (76.1%; 84.1%)	74.4% (70.0%; 79.1%)	70.7% (65.7%; 76.0%)	58.8% (50.9%; 67.9%)
	<b>II</b>	241	91.3% (87.4%; 95.3%)	78.0% (72.5%; 84.0%)	70.2% (63.9%; 77.1%)	64.5% (57.7%; 72.1%)	59.2% (51.9%; 67.4%)	49.7% (38.3%; 64.4%)
	<b>III</b>	236	89.8% (85.6%; 94.1%)	76.2% (70.6%; 82.4%)	71.8% (65.7%; 78.5%)	65.5% (58.9%; 72.9%)	58.9% (51.8%; 66.9%)	41.1% (31.1%; 54.2%)
	<b>IV</b>	661	77.9% (74.6%; 81.2%)	58.2% (54.4%; 62.3%)	48.9% (45.0%; 53.2%)	44.0% (40.0%; 48.4%)	39.0% (34.9%; 43.6%)	27.9% (22.9%; 34.1%)
	<b>X/NA</b>	6,461	71.6% (70.5%; 72.7%)	58.9% (57.6%; 60.1%)	51.2% (49.9%; 52.6%)	46.3% (44.9%; 47.7%)	42.3% (40.9%; 43.8%)	29.4% (27.2%; 31.7%)
Oropharynx C01;C05.1-C05.9;C09-C10	<b>I</b>	500	94.8% (92.6%; 97.1%)	87.5% (84.2%; 90.9%)	80.9% (76.9%; 85.2%)	75.4% (70.8%; 80.4%)	72.3% (67.2%; 77.9%)	59.0% (50.5%; 69.0%)

Net Survival Probability, 2013-2022								
Sub-location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Nasopharynx C11	II	201	91.7% (87.6%; 96.1%)	77.6% (71.5%; 84.2%)	71.5% (64.7%; 79.0%)	66.4% (59.0%; 74.8%)	61.3% (53.4%; 70.4%)	53.0% (39.9%; 70.3%)
	III	190	92.6% (88.6%; 96.9%)	81.6% (75.7%; 87.8%)	76.9% (70.5%; 84.0%)	72.3% (65.2%; 80.1%)	64.9% (57.1%; 73.6%)	46.4% (34.9%; 61.5%)
	IV	357	79.9% (75.6%; 84.3%)	64.1% (59.1%; 69.6%)	56.6% (51.3%; 62.5%)	51.5% (46.1%; 57.6%)	46.6% (40.9%; 53.1%)	35.4% (28.5%; 44.1%)
	X/NA	4,137	73.3% (71.9%; 74.7%)	60.7% (59.1%; 62.3%)	53.5% (51.8%; 55.2%)	48.7% (46.9%; 50.5%)	44.4% (42.5%; 46.3%)	30.8% (27.9%; 34.1%)
	I	5	N<50	N<50	N<50	N<50	N<50	N<50
	II	3	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	7	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	441	85.9% (82.6%; 89.4%)	78.0% (74.0%; 82.2%)	72.5% (68.1%; 77.2%)	70.0% (65.3%; 75.0%)	67.8% (62.9%; 73.1%)	57.2% (50.3%; 65.1%)
	Hypopharynx C12-C13	I	52	98.2% (93.0%; 103.6%)	81.8% (70.8%; 94.5%)	70.9% (57.9%; 86.9%)	63.4% (49.4%; 81.2%)	53.9% (39.3%; 73.9%)
II		37	N<50	N<50	N<50	N<50	N<50	N<50
III		44	N<50	N<50	N<50	N<50	N<50	N<50
IV		298	76.0% (71.2%; 81.2%)	51.2% (45.7%; 57.5%)	39.8% (34.3%; 46.3%)	34.8% (29.2%; 41.3%)	29.9% (24.3%; 36.6%)	17.1% (10.7%; 27.4%)
X/NA		1,964	64.3% (62.1%; 66.5%)	50.3% (48.0%; 52.7%)	41.1% (38.8%; 43.5%)	35.7% (33.4%; 38.2%)	32.1% (29.8%; 34.7%)	19.7% (16.8%; 23.1%)
Larynx (C32)	I	750	98.9% (97.4%; 100.5%)	98.1% (95.9%; 100.4%)	95.8% (92.7%; 98.9%)	94.4% (90.6%; 98.3%)	93.4% (88.9%; 98.1%)	71.2% (60.0%; 84.4%)
	II	93	91.9% (85.6%; 98.7%)	84.0% (75.4%; 93.6%)	72.5% (62.2%; 84.5%)	69.4% (58.1%; 82.9%)	71.8% (59.8%; 86.4%)	63.7% (41.4%; 98.1%)
	III	192	87.7% (82.8%; 92.9%)	81.9% (76.0%; 88.2%)	74.9% (68.0%; 82.4%)	69.2% (61.6%; 77.7%)	66.4% (58.2%; 75.7%)	37.5% (25.9%; 54.1%)
	IV	540	84.1% (80.8%; 87.4%)	68.7% (64.5%; 73.1%)	59.4% (54.8%; 64.2%)	52.6% (47.8%; 57.8%)	48.3% (43.2%; 53.9%)	33.6% (26.8%; 42.1%)
	X/NA	3,238	82.1% (80.7%; 83.6%)	75.0% (73.3%; 76.7%)	69.7% (67.8%; 71.6%)	65.1% (62.9%; 67.3%)	61.9% (59.6%; 64.3%)	42.9% (37.0%; 49.7%)
Nasal cavity and paranasal sinuses (C30- C31)	I	85	94.5% (88.7%; 100.7%)	96.3% (89.9%; 103.2%)	93.7% (84.8%; 103.6%)	91.9% (81.7%; 103.5%)	93.8% (82.7%; 106.5%)	89.6% (65.9%; 121.9%)
	II	79	100.7% (97.1%; 104.3%)	92.1% (84.2%; 100.8%)	88.6% (78.8%; 99.7%)	87.7% (75.7%; 101.6%)	90.6% (77.3%; 106.1%)	44.7% (20.1%; 99.1%)

Net Survival Probability, 2013-2022								
Sub-location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Salivary glands (C07-C08)	III	73	88.9% (81.1%; 97.4%)	78.2% (67.9%; 90.1%)	77.4% (65.7%; 91.2%)	77.7% (65.5%; 92.1%)	80.4% (67.8%; 95.4%)	75.9% (57.9%; 99.4%)
	IV	145	76.2% (69.1%; 84.0%)	60.3% (52.2%; 69.8%)	54.9% (46.4%; 65.1%)	45.4% (36.2%; 56.9%)	40.5% (31.2%; 52.7%)	13.6% (3.8%; 49.0%)
	X/NA	580	78.0% (74.4%; 81.7%)	63.5% (59.2%; 68.0%)	56.3% (51.7%; 61.2%)	52.6% (47.8%; 57.9%)	51.3% (46.2%; 57.0%)	47.9% (39.1%; 58.7%)
	I	115	101.3% (99.6%; 103.0%)	100.6% (96.7%; 104.6%)	99.0% (93.4%; 105.0%)	102.8% (97.0%; 108.9%)	94.8% (82.9%; 108.5%)	81.7% (60.7%; 109.9%)
	II	113	100.4% (97.3%; 103.5%)	93.2% (86.5%; 100.3%)	90.4% (82.3%; 99.3%)	90.4% (81.2%; 100.6%)	87.1% (76.1%; 99.7%)	69.8% (47.9%; 101.8%)
	III	80	98.4% (93.0%; 104.2%)	85.3% (75.6%; 96.4%)	76.5% (64.4%; 90.9%)	79.2% (66.2%; 94.7%)	77.9% (62.8%; 96.6%)	46.8% (25.2%; 86.8%)
	IV	163	86.3% (80.5%; 92.6%)	69.2% (61.4%; 78.0%)	58.2% (49.4%; 68.5%)	46.8% (37.8%; 58.0%)	43.9% (33.8%; 56.9%)	45.8% (32.2%; 65.0%)
Other and ill-defined sites (C14)	X/NA	342	72.2% (67.1%; 77.6%)	60.4% (54.7%; 66.6%)	51.7% (45.6%; 58.6%)	50.0% (43.6%; 57.4%)	44.9% (37.1%; 54.4%)	35.6% (23.3%; 54.6%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	146	53.4% (45.8%; 62.3%)	42.5% (35.0%; 51.8%)	36.1% (28.7%; 45.4%)	29.9% (22.8%; 39.2%)	28.6% (21.4%; 38.1%)	8.5% (3.0%; 24.6%)
<b>Females</b>								
Lip (C00)	I	91	101.2% (96.7%; 105.9%)	96.5% (88.1%; 105.7%)	88.8% (76.7%; 102.9%)	83.2% (68.8%; 100.6%)	86.2% (70.4%; 105.5%)	97.5% (56.2%; 169.1%)
	II	21	N<50	N<50	N<50	N<50	N<50	N<50
	III	11	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	34	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	I	648	95.8% (93.9%; 97.7%)	93.0% (90.5%; 95.6%)	90.8% (87.8%; 93.9%)	88.6% (85.1%; 92.3%)	85.3% (81.2%; 89.7%)	80.9% (72.0%; 90.8%)
	II	324	96.9% (94.3%; 99.6%)	90.1% (86.0%; 94.5%)	86.3% (81.0%; 92.0%)	81.4% (74.7%; 88.7%)	78.2% (70.8%; 86.3%)	69.1% (54.1%; 88.2%)
	III	261	90.3% (86.2%; 94.6%)	77.4% (71.9%; 83.4%)	73.7% (67.7%; 80.2%)	68.9% (62.3%; 76.2%)	68.4% (61.3%; 76.2%)	66.4% (51.6%; 85.5%)

Net Survival Probability, 2013-2022								
Sub-location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Pharynx (C01, C05.1-C05.9, C09-C13)	IV	557	81.0% (77.6%; 84.5%)	64.7% (60.6%; 69.1%)	56.9% (52.5%; 61.7%)	54.9% (50.3%; 59.9%)	51.3% (46.3%; 56.7%)	25.7% (8.8%; 74.9%)
	X/NA	660	52.0% (48.2%; 56.2%)	40.0% (36.2%; 44.3%)	35.8% (32.0%; 40.2%)	30.0% (26.1%; 34.5%)	29.3% (25.3%; 34.0%)	17.7% (10.8%; 29.0%)
	I	274	95.6% (92.9%; 98.4%)	93.5% (90.1%; 97.1%)	86.2% (81.4%; 91.2%)	82.5% (77.0%; 88.4%)	79.6% (73.4%; 86.2%)	55.3% (43.0%; 71.1%)
	II	109	95.0% (90.4%; 99.8%)	90.1% (83.8%; 96.8%)	82.9% (74.9%; 91.7%)	79.6% (70.7%; 89.5%)	78.9% (69.6%; 89.6%)	53.2% (36.2%; 78.3%)
	III	85	96.8% (92.3%; 101.5%)	85.2% (77.2%; 94.0%)	77.7% (68.2%; 88.5%)	76.5% (66.4%; 88.3%)	74.6% (63.6%; 87.6%)	67.2% (47.7%; 94.8%)
	IV	154	78.2% (71.8%; 85.2%)	64.9% (57.6%; 73.3%)	58.5% (50.8%; 67.4%)	52.2% (44.3%; 61.6%)	46.8% (38.7%; 56.5%)	36.0% (26.8%; 48.3%)
	X/NA	2,070	72.7% (70.8%; 74.8%)	61.6% (59.5%; 63.9%)	56.4% (54.1%; 58.7%)	51.5% (49.1%; 54.0%)	47.7% (45.3%; 50.4%)	33.3% (29.2%; 37.9%)
Oropharynx C01;C05.1- C05.9;C09-C10	I	249	95.5% (92.6%; 98.4%)	93.0% (89.4%; 96.8%)	86.4% (81.4%; 91.7%)	83.0% (77.3%; 89.1%)	79.6% (73.2%; 86.6%)	55.2% (42.6%; 71.5%)
	II	100	95.5% (90.9%; 100.3%)	91.0% (84.6%; 97.9%)	84.2% (75.9%; 93.3%)	80.5% (71.3%; 90.9%)	79.5% (69.8%; 90.6%)	58.3% (41.2%; 82.4%)
	III	76	96.2% (91.3%; 101.4%)	84.5% (76.0%; 93.9%)	80.1% (70.4%; 91.2%)	82.2% (72.2%; 93.5%)	78.3% (67.5%; 90.8%)	71.9% (51.1%; 101.1%)
	IV	111	83.1% (76.1%; 90.6%)	66.4% (57.9%; 76.3%)	61.6% (52.6%; 72.0%)	56.1% (46.8%; 67.1%)	51.7% (42.3%; 63.2%)	40.9% (30.0%; 55.7%)
	X/NA	1,524	74.0% (71.7%; 76.3%)	62.4% (59.9%; 65.0%)	57.7% (55.1%; 60.4%)	52.8% (50.1%; 55.8%)	49.4% (46.5%; 52.4%)	34.3% (29.4%; 40.1%)
Nasopharynx C11	I	4	N<50	N<50	N<50	N<50	N<50	N<50
	II	4	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	5	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	167	85.5% (80.1%; 91.3%)	81.0% (75.0%; 87.6%)	78.8% (72.3%; 85.8%)	75.0% (67.7%; 83.2%)	74.4% (66.9%; 82.8%)	64.2% (52.1%; 79.1%)
Hypopharynx C12-C13	I	23	N<50	N<50	N<50	N<50	N<50	N<50
	II	5	N<50	N<50	N<50	N<50	N<50	N<50
	III	7	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
Sub-location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Larynx (C32)	IV	38	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	397	62.7% (58.1%; 67.8%)	50.9% (46.0%; 56.2%)	41.8% (36.9%; 47.3%)	34.8% (29.9%; 40.5%)	28.8% (24.0%; 34.6%)	16.5% (11.3%; 24.0%)
	I	140	96.7% (93.0%; 100.6%)	97.2% (92.8%; 101.7%)	95.9% (90.5%; 101.8%)	94.2% (87.3%; 101.8%)	94.6% (87.0%; 102.9%)	103.9% (90.4%; 119.5%)
	II	19	N<50	N<50	N<50	N<50	N<50	N<50
	III	28	N<50	N<50	N<50	N<50	N<50	N<50
	IV	68	77.4% (67.7%; 88.5%)	63.9% (52.9%; 77.2%)	55.0% (43.4%; 69.8%)	53.3% (41.1%; 69.1%)	49.3% (36.7%; 66.1%)	22.2% (9.4%; 52.3%)
Nasal cavity and paranasal sinuses (C30-C31)	X/NA	619	82.3% (79.2%; 85.6%)	73.6% (69.9%; 77.5%)	67.1% (63.1%; 71.4%)	63.0% (58.7%; 67.7%)	60.5% (55.9%; 65.5%)	49.6% (42.6%; 57.6%)
	I	42	N<50	N<50	N<50	N<50	N<50	N<50
	II	18	N<50	N<50	N<50	N<50	N<50	N<50
	III	23	N<50	N<50	N<50	N<50	N<50	N<50
	IV	38	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	246	73.5% (67.8%; 79.6%)	63.8% (57.4%; 70.9%)	59.8% (53.1%; 67.3%)	57.3% (50.3%; 65.2%)	53.6% (46.3%; 62.1%)	38.4% (27.1%; 54.4%)
Salivary glands (C07-C08)	I	159	100.0% (98.2%; 101.7%)	99.4% (96.6%; 102.3%)	98.7% (94.7%; 102.9%)	98.9% (94.1%; 104.1%)	101.9% (96.9%; 107.2%)	108.9% (94.8%; 125.1%)
	II	94	99.5% (96.3%; 102.9%)	100.4% (96.5%; 104.5%)	97.3% (91.0%; 104.0%)	96.9% (89.6%; 104.9%)	97.7% (89.1%; 107.1%)	92.7% (68.0%; 126.2%)
	III	64	95.2% (88.6%; 102.4%)	94.7% (86.4%; 103.9%)	94.6% (84.7%; 105.6%)	98.6% (88.3%; 110.1%)	85.4% (69.4%; 105.0%)	46.2% (18.3%; 116.6%)
	IV	83	81.2% (72.8%; 90.6%)	80.4% (71.4%; 90.6%)	77.9% (67.9%; 89.2%)	74.6% (63.6%; 87.6%)	73.4% (61.6%; 87.4%)	53.5% (36.7%; 77.9%)
	X/NA	198	77.9% (71.7%; 84.7%)	73.1% (66.1%; 81.0%)	74.1% (66.4%; 82.6%)	71.2% (62.3%; 81.4%)	69.8% (60.3%; 80.9%)	57.5% (40.1%; 82.5%)
	Other and ill-defined sites (C14)	I	0	N<50	N<50	N<50	N<50	N<50
II		0	N<50	N<50	N<50	N<50	N<50	N<50
III		0	N<50	N<50	N<50	N<50	N<50	N<50
IV		0	N<50	N<50	N<50	N<50	N<50	N<50
X/NA		0	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
Sub-location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	<b>X/NA</b>	47	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.



4.2.4. Head & Neck cancer survival by sub-location, stage (Stage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022								
Sub-location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total (C00-C14, C30-C32)</b>		25,832	79.9% (79.4%; 80.4%)	69.8% (69.2%; 70.4%)	63.6% (62.9%; 64.3%)	59.2% (58.5%; 60.0%)	56.0% (55.2%; 56.8%)	42.1% (40.1%; 44.2%)
<b>Males</b>								
<b>Lip (C00)</b>	<b>I</b>	201	99.5% (96.3%; 102.7%)	97.5% (92.4%; 102.8%)	95.3% (88.7%; 102.4%)	93.6% (85.4%; 102.5%)	91.5% (82.1%; 102.1%)	80.8% (49.7%; 131.2%)
	<b>II</b>	50	95.0% (87.1%; 103.5%)	88.9% (78.1%; 101.3%)	81.3% (68.1%; 97.0%)	84.1% (70.4%; 100.3%)	84.3% (69.9%; 101.7%)	92.8% (68.6%; 125.5%)
	<b>III</b>	18	N<50	N<50	N<50	N<50	N<50	N<50
	<b>IV</b>	21	N<50	N<50	N<50	N<50	N<50	N<50
	<b>IVA-B</b>	18	N<50	N<50	N<50	N<50	N<50	N<50
	<b>IVC</b>	3	N<50	N<50	N<50	N<50	N<50	N<50
	<b>X/NA</b>	38	N<50	N<50	N<50	N<50	N<50	N<50
<b>Oral cavity (C02-C05.0, C06)</b>	<b>I</b>	1,022	96.9% (95.5%; 98.3%)	91.6% (89.4%; 93.7%)	87.1% (84.5%; 89.8%)	83.0% (79.9%; 86.2%)	79.3% (75.7%; 83.1%)	57.3% (49.0%; 67.0%)
	<b>II</b>	647	89.1% (86.4%; 91.8%)	82.5% (79.2%; 85.9%)	73.9% (69.9%; 78.0%)	67.3% (62.8%; 72.1%)	62.4% (57.6%; 67.7%)	44.0% (36.0%; 53.9%)
	<b>III</b>	665	82.8% (79.8%; 85.9%)	72.0% (68.3%; 75.8%)	63.5% (59.5%; 67.8%)	58.5% (54.1%; 63.3%)	55.5% (50.7%; 60.7%)	39.3% (31.2%; 49.6%)
	<b>IV</b>	1,810	69.6% (67.4%; 71.8%)	53.3% (50.9%; 55.8%)	44.6% (42.2%; 47.2%)	39.4% (36.9%; 42.0%)	35.7% (33.1%; 38.4%)	23.4% (19.5%; 27.9%)
	<b>IVA-B</b>	1,698	71.7% (69.5%; 74.0%)	55.4% (53.0%; 58.0%)	46.6% (44.1%; 49.3%)	41.1% (38.5%; 43.8%)	37.2% (34.6%; 40.1%)	24.4% (20.4%; 29.2%)
	<b>IVC</b>	113	37.6% (29.6%; 47.9%)	21.7% (15.0%; 31.4%)	14.2% (8.2%; 24.5%)	12.9% (7.2%; 23.2%)	10.5% (5.2%; 21.4%)	FU<10 y
	<b>X/NA</b>	213	60.5% (54.0%; 67.8%)	49.0% (42.3%; 56.8%)	44.2% (37.4%; 52.2%)	38.5% (31.6%; 46.9%)	37.0% (30.1%; 45.5%)	32.0% (22.6%; 45.4%)
<b>Pharynx (C01, C05.1-C05.9, C09-C13)</b>	<b>I</b>	1,000	92.6% (90.8%; 94.5%)	84.2% (81.7%; 86.8%)	77.4% (74.4%; 80.6%)	71.8% (68.4%; 75.5%)	67.5% (63.6%; 71.6%)	52.7% (46.1%; 60.2%)
	<b>II</b>	977	88.4% (86.2%; 90.6%)	78.0% (75.2%; 81.0%)	69.9% (66.6%; 73.3%)	64.2% (60.6%; 68.0%)	59.6% (55.7%; 63.8%)	41.5% (35.1%; 49.1%)
	<b>III</b>	1,325	81.9% (79.7%; 84.1%)	71.8% (69.2%; 74.5%)	66.4% (63.6%; 69.3%)	61.4% (58.4%; 64.6%)	57.9% (54.7%; 61.3%)	39.3% (33.5%; 46.2%)
	<b>IV</b>	4,343	66.9% (65.5%; 68.3%)	51.6% (50.1%; 53.2%)	42.9% (41.4%; 44.5%)	38.5% (36.9%; 40.1%)	34.3% (32.6%; 35.9%)	24.5% (22.4%; 26.8%)
	<b>IVA-B</b>	3,780	70.6% (69.1%; 72.1%)	55.8% (54.2%; 57.5%)	46.9% (45.3%; 48.7%)	42.4% (40.7%; 44.2%)	38.0% (36.2%; 39.8%)	27.1% (24.8%; 29.7%)

Sub-location	Stage	N at risk	Net Survival Probability, 2013-2022					
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Oropharynx C01;C05.1- C05.9;C09-C10	<b>IVC</b>	539	41.0% (37.0%; 45.4%)	21.9% (18.6%; 25.8%)	15.0% (12.1%; 18.5%)	11.3% (8.7%; 14.6%)	8.4% (6.0%; 11.7%)	6.0% (3.7%; 9.6%)
	<b>X/NA</b>	573	62.2% (58.2%; 66.4%)	48.2% (44.1%; 52.6%)	42.3% (38.2%; 46.9%)	36.2% (32.1%; 40.7%)	33.6% (29.5%; 38.3%)	23.6% (18.6%; 30.0%)
	<b>I</b>	854	93.0% (91.0%; 94.9%)	84.9% (82.2%; 87.7%)	79.0% (75.7%; 82.3%)	73.3% (69.6%; 77.3%)	69.8% (65.6%; 74.3%)	53.9% (46.4%; 62.7%)
	<b>II</b>	703	90.8% (88.4%; 93.2%)	80.5% (77.2%; 83.9%)	72.4% (68.5%; 76.4%)	66.1% (61.8%; 70.7%)	61.1% (56.4%; 66.1%)	44.5% (36.2%; 54.7%)
	<b>III</b>	842	81.9% (79.1%; 84.7%)	71.9% (68.7%; 75.3%)	67.0% (63.5%; 70.7%)	62.8% (59.1%; 66.8%)	57.8% (53.8%; 62.1%)	38.2% (29.7%; 49.1%)
	<b>IV</b>	2,594	68.8% (66.9%; 70.6%)	53.9% (51.9%; 55.9%)	46.1% (44.1%; 48.3%)	41.9% (39.9%; 44.1%)	37.5% (35.4%; 39.7%)	27.4% (24.7%; 30.5%)
	<b>IVA-B</b>	2,283	72.0% (70.1%; 73.9%)	57.8% (55.7%; 60.0%)	49.8% (47.7%; 52.1%)	45.7% (43.5%; 48.0%)	41.0% (38.7%; 43.4%)	30.0% (26.9%; 33.4%)
	<b>IVC</b>	282	43.1% (37.6%; 49.4%)	23.4% (18.8%; 29.1%)	18.0% (13.8%; 23.4%)	13.2% (9.6%; 18.3%)	10.8% (7.2%; 16.2%)	8.2% (4.7%; 14.3%)
Nasopharynx C11	<b>X/NA</b>	408	63.2% (58.6%; 68.2%)	49.3% (44.4%; 54.6%)	42.9% (38.1%; 48.4%)	36.7% (31.9%; 42.2%)	35.0% (30.2%; 40.6%)	24.5% (18.6%; 32.2%)
	<b>I</b>	32	N<50	N<50	N<50	N<50	N<50	N<50
	<b>II</b>	88	93.3% (87.7%; 99.2%)	91.0% (84.4%; 98.2%)	87.9% (80.0%; 96.6%)	85.0% (75.7%; 95.4%)	86.2% (76.8%; 96.8%)	67.1% (51.9%; 86.8%)
	<b>III</b>	143	91.0% (86.2%; 96.1%)	88.3% (82.7%; 94.2%)	82.7% (76.1%; 89.9%)	79.3% (72.1%; 87.2%)	80.2% (72.9%; 88.1%)	74.4% (64.4%; 85.9%)
	<b>IV</b>	158	77.3% (70.9%; 84.3%)	67.9% (60.7%; 75.9%)	59.7% (52.1%; 68.4%)	57.6% (49.8%; 66.6%)	51.7% (43.3%; 61.6%)	40.3% (29.1%; 56.0%)
	<b>IVA-B</b>	144	78.5% (71.9%; 85.7%)	69.6% (62.2%; 77.8%)	62.9% (55.1%; 71.9%)	60.5% (52.4%; 69.9%)	55.2% (46.5%; 65.5%)	43.4% (31.0%; 60.8%)
	<b>IVC</b>	14	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	<b>X/NA</b>	37	N<50	N<50	N<50	N<50	N<50	N<50
	<b>I</b>	119	91.0% (85.4%; 96.9%)	80.6% (73.1%; 89.0%)	66.4% (57.4%; 76.7%)	59.2% (49.8%; 70.4%)	51.7% (41.9%; 63.7%)	41.6% (30.4%; 56.9%)
	<b>II</b>	192	76.2% (70.1%; 82.8%)	61.6% (54.6%; 69.6%)	50.7% (43.4%; 59.3%)	46.0% (38.5%; 55.0%)	39.5% (31.8%; 49.0%)	20.2% (12.1%; 33.9%)
	<b>III</b>	340	78.2% (73.7%; 83.0%)	64.6% (59.4%; 70.3%)	58.5% (52.9%; 64.6%)	50.4% (44.2%; 57.3%)	48.6% (42.3%; 55.9%)	26.9% (19.5%; 37.1%)
	<b>IV</b>	1,615	62.8% (60.4%; 65.2%)	46.0% (43.6%; 48.6%)	35.8% (33.4%; 38.4%)	30.9% (28.5%; 33.5%)	27.1% (24.7%; 29.8%)	17.6% (14.6%; 21.1%)
	<b>IVA-B</b>	1,370	67.3% (64.8%; 69.9%)	50.9% (48.2%; 53.7%)	40.3% (37.6%; 43.2%)	35.0% (32.2%; 37.9%)	31.0% (28.3%; 34.0%)	20.1% (16.7%; 24.2%)
	<b>IVC</b>	245	37.3% (31.7%; 44.0%)	18.8% (14.5%; 24.5%)	11.1% (7.6%; 16.0%)	8.3% (5.2%; 13.0%)	5.2% (2.8%; 9.6%)	3.2% (1.4%; 7.3%)

Sub-location	Stage	Net Survival Probability, 2013-2022						
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Larynx (C32)</b>	<b>X/NA</b>	132	56.3% (48.3%; 65.6%)	45.6% (37.7%; 55.3%)	40.7% (32.7%; 50.5%)	34.2% (26.4%; 44.3%)	30.2% (22.5%; 40.4%)	21.3% (12.7%; 35.7%)
	<b>I</b>	1,728	97.6% (96.5%; 98.7%)	96.1% (94.5%; 97.7%)	93.5% (91.4%; 95.7%)	91.5% (88.8%; 94.4%)	90.1% (86.8%; 93.4%)	67.8% (57.3%; 80.3%)
	<b>II</b>	741	89.9% (87.5%; 92.4%)	82.9% (79.7%; 86.2%)	76.7% (73.0%; 80.5%)	70.6% (66.5%; 75.1%)	67.7% (63.2%; 72.6%)	50.0% (41.9%; 59.6%)
	<b>III</b>	738	81.7% (78.7%; 84.7%)	73.5% (70.0%; 77.1%)	66.2% (62.4%; 70.4%)	60.6% (56.4%; 65.1%)	55.9% (51.4%; 60.9%)	31.4% (23.8%; 41.3%)
	<b>IV</b>	1,225	71.1% (68.5%; 73.8%)	56.6% (53.7%; 59.7%)	48.7% (45.7%; 52.0%)	42.8% (39.7%; 46.1%)	39.0% (35.8%; 42.5%)	25.1% (20.9%; 30.0%)
	<b>IVA-B</b>	1,104	73.7% (71.1%; 76.5%)	60.3% (57.2%; 63.5%)	52.2% (49.0%; 55.6%)	46.1% (42.8%; 49.6%)	41.9% (38.5%; 45.7%)	26.8% (22.3%; 32.1%)
	<b>IVC</b>	121	47.0% (38.7%; 57.0%)	23.1% (16.4%; 32.5%)	16.4% (10.5%; 25.6%)	11.5% (6.1%; 21.5%)	11.7% (6.2%; 21.8%)	FU<10 y
<b>Nasal cavity and paranasal sinuses (C30-C31)</b>	<b>X/NA</b>	380	74.1% (69.5%; 78.9%)	67.7% (62.6%; 73.1%)	61.6% (56.1%; 67.6%)	56.7% (50.8%; 63.2%)	53.8% (47.6%; 60.9%)	37.9% (29.0%; 49.6%)
	<b>I</b>	111	95.7% (90.9%; 100.7%)	92.4% (85.8%; 99.6%)	88.2% (79.7%; 97.5%)	87.1% (77.8%; 97.6%)	89.0% (79.0%; 100.3%)	86.9% (66.6%; 113.4%)
	<b>II</b>	110	99.1% (95.1%; 103.3%)	92.7% (85.7%; 100.2%)	88.1% (79.0%; 98.2%)	86.4% (75.5%; 98.8%)	87.1% (75.3%; 100.7%)	65.9% (37.1%; 117.0%)
	<b>III</b>	122	87.8% (81.3%; 94.8%)	79.9% (71.7%; 89.0%)	72.9% (62.9%; 84.5%)	71.7% (61.1%; 84.2%)	73.5% (62.6%; 86.3%)	63.5% (46.1%; 87.3%)
	<b>IV</b>	332	69.4% (64.4%; 74.9%)	52.7% (47.1%; 58.9%)	45.8% (40.2%; 52.3%)	40.7% (34.8%; 47.6%)	38.9% (32.8%; 46.1%)	22.8% (11.9%; 43.7%)
	<b>IVA-B</b>	292	72.6% (67.3%; 78.2%)	56.0% (50.1%; 62.6%)	49.6% (43.5%; 56.5%)	44.1% (37.7%; 51.6%)	41.7% (35.1%; 49.5%)	28.0% (15.8%; 49.7%)
	<b>IVC</b>	41	N<50	N<50	N<50	N<50	N<50	N<50
<b>Salivary glands (C07-C08)</b>	<b>X/NA</b>	286	81.6% (76.9%; 86.7%)	66.2% (60.3%; 72.6%)	60.2% (53.9%; 67.2%)	55.4% (48.7%; 63.0%)	51.8% (44.6%; 60.1%)	49.7% (39.9%; 61.9%)
	<b>I</b>	120	101.5% (99.9%; 103.2%)	101.2% (97.5%; 105.1%)	100.0% (94.6%; 105.7%)	103.5% (97.9%; 109.4%)	96.8% (85.1%; 110.0%)	77.9% (52.3%; 115.9%)
	<b>II</b>	123	97.4% (93.1%; 101.9%)	92.1% (85.5%; 99.4%)	87.0% (78.7%; 96.3%)	87.4% (78.2%; 97.7%)	82.5% (71.5%; 95.2%)	66.7% (45.8%; 97.2%)
	<b>III</b>	105	91.8% (85.1%; 99.0%)	83.2% (74.1%; 93.5%)	73.7% (62.0%; 87.6%)	77.1% (64.2%; 92.6%)	63.6% (44.4%; 91.2%)	39.2% (19.4%; 79.1%)
	<b>IV</b>	279	71.5% (66.0%; 77.5%)	54.2% (48.0%; 61.2%)	45.0% (38.5%; 52.6%)	36.1% (29.6%; 44.0%)	31.9% (25.0%; 40.6%)	33.0% (24.0%; 45.2%)
	<b>IVA-B</b>	212	78.4% (72.4%; 84.8%)	59.5% (52.3%; 67.6%)	49.5% (41.9%; 58.5%)	40.3% (32.7%; 49.6%)	35.2% (27.1%; 45.8%)	36.7% (26.1%; 51.6%)
	<b>IVC</b>	67	49.8% (38.8%; 63.9%)	37.7% (27.2%; 52.3%)	30.3% (20.2%; 45.4%)	22.5% (13.0%; 38.9%)	21.5% (12.0%; 38.3%)	FU<10 y
<b>X/NA</b>	186	85.4% (79.8%; 91.3%)	72.6% (65.6%; 80.4%)	63.4% (55.6%; 72.2%)	62.1% (54.0%; 71.3%)	61.3% (52.9%; 71.1%)	53.8% (39.1%; 74.1%)	

		Net Survival Probability, 2013-2022							
Sub-location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
<b>Other and ill-defined sites (C14)</b>	<b>I</b>	0	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>II</b>	0	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>III</b>	0	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>IV</b>	1	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>IVA-B</b>	0	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>IVC</b>	1	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>X/NA</b>	146	53.4% (45.8%; 62.3%)	42.5% (35.0%; 51.8%)	36.1% (28.7%; 45.4%)	29.9% (22.8%; 39.1%)	28.3% (21.2%; 37.7%)	8.5% (3.0%; 24.6%)	
<b>Females</b>									
<b>Lip (C00)</b>	<b>I</b>	102	100.3% (95.8%; 105.1%)	96.4% (88.6%; 104.9%)	88.6% (77.5%; 101.4%)	82.3% (69.2%; 98.0%)	84.9% (70.7%; 102.0%)	94.7% (58.3%; 154.0%)	
	<b>II</b>	24	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>III</b>	11	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>IV</b>	13	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>IVA-B</b>	13	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>IVC</b>	0	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>X/NA</b>	16	N<50	N<50	N<50	N<50	N<50	N<50	
<b>Oral cavity (C02-C05.0, C06)</b>	<b>I</b>	690	95.8% (94.0%; 97.7%)	92.7% (90.3%; 95.3%)	90.0% (87.0%; 93.2%)	87.0% (83.5%; 90.8%)	83.5% (79.4%; 87.9%)	79.4% (71.0%; 88.8%)	
	<b>II</b>	387	92.8% (89.6%; 96.0%)	85.9% (81.7%; 90.4%)	80.8% (75.6%; 86.3%)	75.8% (69.5%; 82.6%)	73.6% (66.8%; 81.0%)	65.1% (52.0%; 81.5%)	
	<b>III</b>	325	82.8% (78.4%; 87.5%)	69.3% (63.9%; 75.1%)	65.3% (59.6%; 71.6%)	59.7% (53.5%; 66.6%)	59.4% (52.8%; 66.7%)	57.1% (44.4%; 73.4%)	
	<b>IV</b>	921	65.0% (61.8%; 68.3%)	50.0% (46.7%; 53.6%)	43.9% (40.5%; 47.6%)	41.1% (37.6%; 45.0%)	38.9% (35.2%; 43.0%)	16.8% (6.0%; 47.3%)	
	<b>IVA-B</b>	879	65.7% (62.5%; 69.1%)	51.2% (47.8%; 54.8%)	45.0% (41.5%; 48.8%)	42.3% (38.7%; 46.3%)	40.0% (36.2%; 44.2%)	17.3% (6.2%; 48.8%)	
	<b>IVC</b>	43	N<50	N<50	N<50	N<50	N<50	N<50	
	<b>X/NA</b>	125	61.0% (52.7%; 70.7%)	51.2% (42.5%; 61.6%)	48.1% (39.4%; 58.9%)	42.1% (33.3%; 53.2%)	39.9% (31.0%; 51.3%)	26.1% (16.0%; 42.5%)	

Sub-location	Stage	N at risk	Net Survival Probability, 2013-2022					
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Pharynx (C01, C05.1-C05.9, C09-C13)	I	443	93.1% (90.6%; 95.7%)	90.0% (86.8%; 93.3%)	84.0% (79.9%; 88.2%)	80.6% (75.9%; 85.5%)	77.8% (72.7%; 83.4%)	57.5% (47.1%; 70.0%)
	II	405	90.1% (87.0%; 93.4%)	81.0% (76.9%; 85.3%)	77.6% (73.1%; 82.4%)	72.7% (67.6%; 78.1%)	70.7% (65.3%; 76.5%)	49.4% (39.6%; 61.5%)
	III	452	80.7% (77.0%; 84.7%)	71.6% (67.3%; 76.1%)	65.2% (60.5%; 70.2%)	61.4% (56.4%; 66.8%)	58.0% (52.7%; 63.8%)	46.9% (37.7%; 58.5%)
	IV	1,197	66.7% (64.0%; 69.5%)	53.7% (50.8%; 56.7%)	46.5% (43.6%; 49.6%)	42.2% (39.3%; 45.4%)	38.0% (35.0%; 41.2%)	26.5% (22.1%; 31.8%)
	IVA-B	1,079	70.4% (67.7%; 73.3%)	57.3% (54.3%; 60.4%)	50.2% (47.1%; 53.5%)	45.4% (42.3%; 48.8%)	41.0% (37.8%; 44.5%)	28.5% (23.7%; 34.3%)
	IVC	108	30.9% (23.3%; 41.0%)	20.8% (14.4%; 30.1%)	12.8% (7.7%; 21.1%)	11.8% (7.0%; 20.0%)	9.8% (5.4%; 17.6%)	7.7% (3.9%; 15.5%)
	X/NA	212	69.0% (62.9%; 75.8%)	57.2% (50.6%; 64.6%)	56.1% (49.4%; 63.8%)	46.6% (39.6%; 55.0%)	44.2% (37.0%; 52.7%)	28.3% (20.7%; 38.6%)
Oropharynx C01;C05.1- C05.9;C09-C10	I	388	93.8% (91.2%; 96.5%)	90.4% (87.0%; 93.8%)	85.1% (80.8%; 89.5%)	81.9% (77.0%; 87.1%)	79.1% (73.6%; 85.0%)	58.1% (47.1%; 71.6%)
	II	308	90.3% (86.8%; 94.0%)	80.8% (76.1%; 85.8%)	77.4% (72.2%; 83.0%)	71.7% (65.8%; 78.1%)	69.3% (63.0%; 76.1%)	47.6% (37.4%; 60.5%)
	III	329	81.6% (77.3%; 86.1%)	72.5% (67.5%; 77.9%)	68.4% (63.1%; 74.3%)	65.8% (60.1%; 72.0%)	62.0% (55.9%; 68.7%)	50.7% (39.1%; 65.6%)
	IV	865	69.0% (66.0%; 72.3%)	55.2% (51.8%; 58.7%)	48.3% (45.0%; 52.0%)	44.1% (40.7%; 47.9%)	40.5% (37.0%; 44.3%)	29.6% (24.1%; 36.4%)
	IVA-B	782	72.6% (69.5%; 75.9%)	59.1% (55.6%; 62.8%)	52.1% (48.5%; 55.9%)	47.4% (43.7%; 51.4%)	43.7% (40.0%; 47.8%)	32.0% (26.0%; 39.3%)
	IVC	73	33.3% (24.1%; 46.0%)	18.2% (11.2%; 29.6%)	12.1% (6.5%; 22.6%)	12.3% (6.6%; 22.9%)	9.4% (4.5%; 19.3%)	6.6% (2.7%; 16.1%)
	X/NA	172	69.7% (62.9%; 77.2%)	56.6% (49.3%; 65.0%)	56.3% (48.9%; 64.9%)	50.0% (42.2%; 59.3%)	48.4% (40.4%; 57.9%)	30.3% (21.6%; 42.5%)
Nasopharynx C11	I	13	N<50	N<50	N<50	N<50	N<50	N<50
	II	47	N<50	N<50	N<50	N<50	N<50	N<50
	III	48	N<50	N<50	N<50	N<50	N<50	N<50
	IV	62	73.0% (62.5%; 85.2%)	70.1% (59.3%; 82.8%)	64.8% (53.5%; 78.6%)	62.8% (51.1%; 77.1%)	60.1% (48.0%; 75.3%)	50.5% (36.0%; 70.8%)
	IVA-B	55	75.0% (64.1%; 87.7%)	71.7% (60.4%; 85.1%)	70.0% (58.4%; 84.0%)	70.5% (58.8%; 84.5%)	67.3% (54.8%; 82.7%)	55.7% (39.5%; 78.5%)
	IVC	7	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	12	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
Sub-location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Hypopharynx C12-C13	I	44	N<50	N<50	N<50	N<50	N<50	N<50
	II	51	79.4% (68.6%; 92.0%)	65.5% (53.1%; 80.9%)	64.0% (51.3%; 79.9%)	61.4% (48.1%; 78.3%)	57.9% (43.8%; 76.6%)	28.9% (10.3%; 80.8%)
	III	76	73.1% (63.5%; 84.0%)	63.0% (52.7%; 75.4%)	45.2% (34.6%; 59.1%)	32.9% (22.5%; 47.9%)	31.4% (21.1%; 46.8%)	19.0% (9.3%; 39.0%)
	IV	271	57.4% (51.8%; 63.7%)	45.0% (39.2%; 51.5%)	36.4% (30.7%; 43.1%)	31.1% (25.6%; 37.8%)	24.1% (18.8%; 30.8%)	10.7% (6.1%; 18.7%)
	IVA-B	243	62.0% (56.1%; 68.5%)	48.1% (42.0%; 55.0%)	39.4% (33.3%; 46.5%)	33.4% (27.5%; 40.7%)	25.6% (20.0%; 32.9%)	11.3% (6.4%; 19.8%)
	IVC	28	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	28	N<50	N<50	N<50	N<50	N<50	N<50
Larynx (C32)	I	295	96.6% (93.9%; 99.3%)	95.8% (92.5%; 99.3%)	93.1% (88.8%; 97.5%)	92.1% (87.1%; 97.4%)	93.6% (88.2%; 99.3%)	100.8% (89.2%; 113.8%)
	II	139	91.1% (86.2%; 96.4%)	81.9% (75.2%; 89.1%)	77.7% (70.2%; 85.9%)	70.5% (62.0%; 80.1%)	67.6% (58.6%; 77.9%)	47.5% (34.9%; 64.7%)
	III	145	84.7% (78.6%; 91.3%)	74.6% (67.3%; 82.7%)	64.6% (56.4%; 74.0%)	60.0% (51.1%; 70.3%)	50.6% (41.1%; 62.3%)	38.5% (24.8%; 59.6%)
	IV	221	68.6% (62.7%; 75.2%)	54.8% (48.3%; 62.1%)	46.0% (39.4%; 53.6%)	41.3% (34.7%; 49.2%)	39.8% (33.1%; 47.8%)	20.2% (13.0%; 31.4%)
	IVA-B	197	71.3% (65.1%; 78.1%)	57.6% (50.8%; 65.2%)	49.0% (42.1%; 57.1%)	43.8% (36.8%; 52.2%)	42.1% (35.0%; 50.7%)	22.6% (14.6%; 34.9%)
	IVC	24	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	74	78.5% (69.3%; 88.9%)	71.7% (61.5%; 83.6%)	64.4% (53.5%; 77.5%)	59.4% (47.2%; 74.6%)	52.6% (40.2%; 68.6%)	45.1% (30.9%; 65.8%)
Nasal cavity and paranasal sinuses (C30- C31)	I	57	96.1% (90.5%; 102.1%)	97.8% (92.1%; 103.9%)	94.2% (85.5%; 103.7%)	93.6% (84.0%; 104.3%)	94.6% (84.9%; 105.4%)	83.8% (61.0%; 115.1%)
	II	24	N<50	N<50	N<50	N<50	N<50	N<50
	III	34	N<50	N<50	N<50	N<50	N<50	N<50
	IV	119	56.0% (47.4%; 66.1%)	45.6% (36.8%; 56.6%)	43.2% (34.2%; 54.4%)	36.7% (27.7%; 48.7%)	35.9% (26.7%; 48.3%)	16.8% (7.1%; 39.6%)
	IVA-B	103	60.7% (51.6%; 71.5%)	49.7% (40.1%; 61.7%)	48.0% (38.2%; 60.3%)	40.5% (30.5%; 53.7%)	39.6% (29.4%; 53.3%)	17.5% (7.2%; 42.7%)
	IVC	16	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	133	83.9% (77.4%; 91.0%)	72.4% (64.5%; 81.4%)	69.8% (61.4%; 79.5%)	66.6% (57.7%; 77.0%)	61.0% (51.4%; 72.3%)	47.6% (33.6%; 67.4%)
Salivary glands (C07-C08)	I	167	100.0% (98.4%; 101.7%)	99.6% (96.9%; 102.3%)	99.0% (95.2%; 102.9%)	99.1% (94.5%; 103.9%)	100.7% (95.3%; 106.5%)	107.8% (94.9%; 122.5%)

Sub-location	Stage	Net Survival Probability, 2013-2022						
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Other and ill-defined sites (C14)	II	109	99.1% (95.8%; 102.5%)	100.4% (96.6%; 104.4%)	98.0% (92.3%; 104.1%)	99.4% (92.7%; 106.5%)	102.2% (94.4%; 110.6%)	86.4% (61.0%; 122.4%)
	III	81	92.2% (85.3%; 99.6%)	91.3% (82.9%; 100.5%)	91.4% (81.6%; 102.5%)	92.2% (81.0%; 105.0%)	79.7% (65.3%; 97.2%)	53.0% (24.3%; 115.5%)
	IV	144	69.5% (61.8%; 78.2%)	64.1% (55.7%; 73.9%)	64.1% (55.1%; 74.5%)	60.9% (51.1%; 72.6%)	59.1% (48.6%; 72.0%)	35.3% (20.2%; 61.7%)
	IVA-B	114	77.9% (69.9%; 86.9%)	73.8% (64.6%; 84.2%)	74.1% (64.3%; 85.4%)	70.1% (59.1%; 83.3%)	67.2% (55.3%; 81.8%)	43.3% (24.4%; 76.7%)
	IVC	30	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	98	88.1% (81.1%; 95.7%)	85.3% (77.1%; 94.4%)	83.6% (74.6%; 93.7%)	79.4% (67.9%; 92.8%)	79.4% (67.3%; 93.7%)	79.4% (56.7%; 111.2%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	47	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

## 5. CANCER SURVIVAL TRENDS



### 5.1. Head & Neck cancer survival trends: by tumour stage

5.1.1. Head & Neck cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
<b>2008-2012</b>	<b>I</b>	1,736	96.3% (95.2%; 97.5%)	88.6% (86.5%; 90.7%)	82.4% (79.8%; 85.2%)	647	96.5% (94.8%; 98.3%)	88.3% (85.2%; 91.5%)	83.0% (79.2%; 86.9%)
	<b>II</b>	1,117	88.0% (85.9%; 90.1%)	71.8% (68.8%; 74.9%)	63.3% (59.9%; 66.8%)	393	89.7% (86.4%; 93.1%)	80.7% (76.2%; 85.3%)	71.9% (66.6%; 77.6%)
	<b>III</b>	1,325	81.8% (79.7%; 84.1%)	60.3% (57.5%; 63.3%)	51.1% (48.2%; 54.3%)	403	87.0% (83.5%; 90.6%)	70.1% (65.3%; 75.2%)	57.5% (52.2%; 63.5%)
	<b>IV</b>	3,690	69.4% (67.8%; 70.9%)	43.3% (41.6%; 45.0%)	33.2% (31.5%; 34.9%)	1,043	70.6% (67.8%; 73.5%)	47.4% (44.3%; 50.7%)	39.6% (36.5%; 43.0%)
	<b>IVA-B</b>	3,315	71.9% (70.3%; 73.5%)	46.1% (44.3%; 47.9%)	35.8% (34.0%; 37.6%)	945	73.4% (70.6%; 76.4%)	49.9% (46.6%; 53.3%)	41.9% (38.6%; 45.5%)
	<b>IVC</b>	375	47.1% (42.2%; 52.5%)	18.6% (14.8%; 23.2%)	9.8% (7.0%; 13.6%)	98	42.9% (34.0%; 54.1%)	23.2% (15.3%; 35.3%)	17.4% (10.7%; 28.3%)
	<b>X/NA</b>	1,797	75.2% (73.1%; 77.3%)	58.1% (55.6%; 60.7%)	50.2% (47.4%; 53.1%)	685	75.7% (72.4%; 79.2%)	60.9% (56.8%; 65.2%)	53.3% (48.9%; 58.2%)
<b>2013-2017</b>	<b>I</b>	1,948	96.0% (94.9%; 97.1%)	87.0% (85.1%; 89.1%)	81.4% (78.9%; 83.9%)	763	95.4% (93.6%; 97.2%)	88.6% (85.7%; 91.6%)	83.2% (79.6%; 87.0%)
	<b>II</b>	1,232	89.5% (87.6%; 91.4%)	74.5% (71.7%; 77.3%)	65.5% (62.3%; 68.8%)	492	90.1% (87.2%; 93.1%)	77.8% (73.5%; 82.3%)	72.2% (67.3%; 77.5%)
	<b>III</b>	1,409	81.7% (79.5%; 83.8%)	65.2% (62.4%; 68.0%)	56.1% (53.1%; 59.3%)	445	83.3% (79.6%; 87.1%)	66.2% (61.5%; 71.2%)	57.5% (52.4%; 63.1%)
	<b>IV</b>	4,159	68.9% (67.5%; 70.4%)	44.0% (42.4%; 45.6%)	34.7% (33.2%; 36.4%)	1,311	67.6% (65.0%; 70.2%)	47.1% (44.3%; 50.0%)	40.2% (37.4%; 43.3%)
	<b>IVA-B</b>	3,746	72.0% (70.5%; 73.5%)	47.2% (45.5%; 48.9%)	37.5% (35.8%; 39.2%)	1,206	69.9% (67.3%; 72.7%)	49.4% (46.4%; 52.5%)	42.0% (39.0%; 45.2%)
	<b>IVC</b>	418	41.0% (36.4%; 46.1%)	15.1% (11.9%; 19.2%)	9.7% (6.9%; 13.5%)	106	40.1% (31.7%; 50.7%)	20.5% (14.0%; 29.9%)	18.0% (11.9%; 27.2%)
	<b>X/NA</b>	1,129	71.0% (68.3%; 73.9%)	52.8% (49.6%; 56.2%)	45.4% (42.0%; 49.0%)	434	73.1% (68.7%; 77.7%)	60.8% (55.9%; 66.3%)	51.2% (45.8%; 57.2%)
<b>2018-2022</b>	<b>I</b>	2,194	96.7% (95.7%; 97.7%)	89.6% (87.6%; 91.6%)	83.9% (80.1%; 87.8%)	984	96.5% (95.0%; 98.0%)	91.2% (88.5%; 94.0%)	89.5% (85.9%; 93.2%)



Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	<b>II</b>	1,409	90.3% (88.6%; 92.1%)	74.9% (72.0%; 77.8%)	65.9% (61.9%; 70.1%)	592	94.8% (92.6%; 97.0%)	84.4% (80.5%; 88.4%)	77.4% (71.5%; 83.7%)
	<b>III</b>	1,558	83.5% (81.5%; 85.5%)	67.5% (64.8%; 70.4%)	60.7% (56.6%; 65.1%)	600	83.4% (80.2%; 86.7%)	68.2% (63.9%; 72.8%)	62.5% (57.1%; 68.4%)
	<b>IV</b>	3,830	67.8% (66.3%; 69.4%)	44.8% (43.0%; 46.6%)	36.3% (34.2%; 38.5%)	1,298	64.3% (61.7%; 67.1%)	46.5% (43.6%; 49.6%)	38.9% (35.4%; 42.7%)
	<b>IVA-B</b>	3,341	71.2% (69.7%; 72.9%)	48.6% (46.7%; 50.6%)	39.9% (37.6%; 42.3%)	1,175	67.5% (64.7%; 70.3%)	50.0% (46.9%; 53.3%)	41.9% (38.1%; 45.9%)
	<b>IVC</b>	465	43.7% (39.3%; 48.6%)	18.1% (14.6%; 22.6%)	11.2% (7.9%; 15.9%)	115	33.1% (25.4%; 43.2%)	10.9% (5.8%; 20.4%)	FU<5y
	<b>X/NA</b>	677	68.5% (65.0%; 72.3%)	51.1% (46.9%; 55.6%)	43.2% (38.5%; 48.6%)	270	72.8% (67.5%; 78.5%)	61.8% (55.7%; 68.5%)	53.2% (46.0%; 61.7%)

## 6. CANCER MORTALITY



### 6.1. Head & Neck cancer mortality: by region

6.1.1. Head & Neck cancer mortality\* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
<b>Belgium</b>	0	0	0	1	0	1	0	0	4	11	26	51	78	98	84	61	41	30	17	3	506	9.6
	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.3]	[0.0]	[0.0]	[1.1]	[2.9]	[6.5]	[12.6]	[21.5]	[32.0]	[31.7]	[35.0]	[31.4]	[38.6]	[60.6]	[55.0]	[8.9]	(8.7; 10.4)
Brussels	0	0	0	0	0	0	0	0	0	1	2	4	6	2	6	3	7	3	3	0	37	10.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[5.0]	[11.7]	[22.0]	[9.6]	[35.9]	[26.1]	[82.8]	[59.4]	[137.9]	[0.0]	[6.2]	(6.7; 13.3)
Flanders	0	0	0	1	0	0	0	0	2	6	14	30	49	64	53	39	31	19	11	1	320	9.7
	[0.0]	[0.0]	[0.0]	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.8]	[6.0]	[12.3]	[22.2]	[34.1]	[32.7]	[34.2]	[35.9]	[36.8]	[60.0]	[27.9]	[9.7]	(8.6; 10.8)
Wallonia	0	0	0	0	0	1	0	0	2	4	10	17	23	32	25	19	3	8	3	2	149	9.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.7]	[3.2]	[8.1]	[13.6]	[20.0]	[32.7]	[28.9]	[39.2]	[8.3]	[38.2]	[39.6]	[142.2]	[8.3]	(7.7; 10.8)
Females																						
<b>Belgium</b>	0	0	0	0	0	0	0	0	0	3	7	14	18	29	33	24	22	15	5	3	173	2.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.8]	[3.5]	[4.8]	[8.9]	[11.1]	[11.3]	[11.9]	[11.1]	[7.5]	[15.6]	[3.0]	(2.3; 3.2)
Brussels	0	0	0	0	0	0	0	0	0	0	2	1	2	2	2	3	2	2	1	0	17	3.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[5.4]	[3.0]	[6.7]	[8.2]	[9.3]	[18.5]	[14.6]	[19.7]	[17.4]	[0.0]	[2.7]	(1.8; 5.1)

Region	N [CR]																				ESR2013 (95%CI)		
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages	
Flanders	0	0	0	0	0	0	0	0	0	2	3	10	11	22	21	14	15	6	3	3	110	2.9	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[1.3]	[4.2]	[5.0]	[11.4]	[12.1]	[10.5]	[12.9]	[7.1]	[7.5]	[26.7]	[3.3]	(2.4; 3.5)
Wallonia	0	0	0	0	0	0	0	0	0	1	2	3	5	5	10	7	5	7	1	0	46	2.3	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.6]	[2.4]	[4.1]	[4.6]	[9.9]	[11.0]	[9.1]	[17.5]	[4.9]	[0.0]	[2.5]	(1.6; 3.0)	

## 7. CANCER MORTALITY TRENDS



### 7.1. Head & Neck cancer mortality trends: by region

7.1.1. Head & Neck cancer mortality\* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	601	636	620	569	594	616	585	572	624	642	626	600	603	565	539	544	552	506			
	<b>CR</b>	11.8	12.4	12.1	11.0	11.4	11.7	11.0	10.7	11.5	11.8	11.4	10.9	10.9	10.1	9.6	9.7	9.8	8.9			
	<b>ESR2013</b>	14.5	14.9	14.3	13.0	13.2	13.5	13.0	12.3	13.3	13.8	12.8	12.2	12.3	11.1	10.5	10.6	10.5	9.6	-2.4 (-2.9; -1.9)	2004-2021	
																				-1.6 (-2.2; -1.0)	2004-2017	
																					-4.8 (-7.0; -2.6)	2018-2021
Brussels	<b>N</b>	60	52	61	61	56	58	49	53	65	54	55	53	53	53	49	53	38	37			
	<b>CR</b>	12.5	10.8	12.5	12.3	11.1	11.2	9.3	9.8	11.8	9.6	9.7	9.3	9.1	9.1	8.4	8.9	6.4	6.2			
	<b>ESR2013</b>	17.7	15.9	17.9	17.6	16.0	16.0	13.9	15.5	17.5	15.7	15.1	14.9	15.6	13.7	13.4	13.8	10.0	10.0	-2.7 (-3.6; -1.7)	2004-2021	
																				-0.8 (-2.1; 0.5)	2004-2015	
																					-6.4 (-8.8; -3.9)	2016-2021
Flanders	<b>N</b>	365	353	350	328	319	343	350	341	348	372	384	391	376	348	327	328	343	320			
	<b>CR</b>	12.3	11.8	11.7	10.9	10.5	11.2	11.3	11.0	11.1	11.8	12.1	12.3	11.7	10.8	10.1	10.1	10.5	9.7			
	<b>ESR2013</b>	14.9	13.6	13.5	12.5	11.7	12.6	12.7	11.9	12.3	13.0	12.8	12.8	12.3	11.2	10.2	10.4	10.5	9.7	-2.8 (-3.6; -2.0)	2004-2021	
Wallonia	<b>N</b>	176	231	209	180	219	215	186	178	211	216	187	156	174	164	163	163	171	149			
	<b>CR</b>	10.7	14.0	12.6	10.8	13.1	12.7	10.9	10.4	12.2	12.5	10.7	8.9	9.9	9.3	9.2	9.2	9.6	8.3			

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
<b>ESR2013</b>	12.9	16.7	15.0	13.0	15.4	14.7	13.2	12.4	14.2	14.7	12.3	10.0	11.3	10.5	10.4	10.4	10.7	9.2	-1.7 (-2.3; -1.1)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Head & Neck cancer mortality\* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	176	155	150	154	164	163	169	171	183	191	177	203	191	222	172	194	151	173			
	<b>CR</b>	3.3	2.9	2.8	2.9	3.0	3.0	3.1	3.1	3.3	3.4	3.1	3.6	3.3	3.9	3.0	3.3	2.6	3.0			
	<b>ESR2013</b>	3.4	3.0	2.9	2.9	3.0	2.9	3.1	3.1	3.3	3.4	3.1	3.4	3.2	3.7	2.7	3.1	2.4	2.8	-1.0 (-1.8; -0.1)	2004-2021	
																				0.8 (-0.3; 1.8)	2004-2017	
																					-6.3 (-10.0; -2.5)	2018-2021
Brussels	<b>N</b>	29	23	21	20	15	18	17	18	20	14	15	19	28	27	12	16	13	17			
	<b>CR</b>	5.6	4.4	4.0	3.7	2.8	3.3	3.0	3.1	3.4	2.4	2.5	3.2	4.6	4.4	2.0	2.6	2.1	2.7			
	<b>ESR2013</b>	6.2	4.5	4.8	4.3	2.9	3.9	3.1	3.6	4.4	2.9	3.1	4.0	5.9	5.8	2.4	3.3	2.6	3.4			
																					-2.1 (-3.9; -0.2)	2004-2021
Flanders	<b>N</b>	78	81	68	85	87	86	89	87	98	112	94	114	115	121	103	108	104	110			
	<b>CR</b>	2.6	2.6	2.2	2.7	2.8	2.7	2.8	2.7	3.0	3.5	2.9	3.5	3.5	3.7	3.1	3.2	3.1	3.3			
	<b>ESR2013</b>	2.6	2.6	2.2	2.7	2.7	2.6	2.8	2.7	3.0	3.3	2.8	3.2	3.2	3.3	2.7	2.9	2.7	2.9			
																					-2.0 (-4.5; 0.5)	2004-2021
																					2.2 (1.1; 3.2)	2004-2016
																					-2.8 (-5.6; 0.0)	2017-2021
Wallonia	<b>N</b>	69	51	61	49	62	59	63	66	65	65	68	70	48	74	57	70	34	46			
	<b>CR</b>	4.0	2.9	3.5	2.8	3.5	3.3	3.5	3.6	3.6	3.6	3.7	3.8	2.6	4.0	3.1	3.8	1.8	2.5			
	<b>ESR2013</b>	4.1	3.1	3.6	2.9	3.6	3.3	3.4	3.7	3.5	3.7	3.6	3.7	2.5	3.9	2.9	3.5	1.7	2.3			
																					0.7 (-0.1; 1.4)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021).

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024